書籍詳細

Part 1 β遮断薬のプロファイル

P.34 掲載の参考文献

• 1) Cruickshank JM, Prichard BNC:Historical. In:β-blockers in Clinical Practice, Churchill Livingstone, Edinburgh, 1988, p.1-p.8

• 2) Ahlquist RP:A study of the adrenotropic receptors. Am J Physiol 153:586-600, 1948
  pubmed

• 3) Powell CE, Slater IH:Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther 122:480-488, 1958
  pubmed

• 4) Black JW, Stephenson JS:Pharmacology of new β-receptor-blocking compound (Nethalide). Lancet ii:311-314, 1962

• 5) Greenberg G, Brennan PJ, Miall WE:Effects of diuretic and β-blocker therapy in the Medical Research Council Trial. Am J Med 76 (2A):S45-S51, 1984

• 6) Aellig WH:Pindolol-A β-adrenoceptor blocking drugs with partial agonist activity:clinical pharmacological considerations. Br J Clin Pharmacol 13 (Suppl 2):S187-S189, 1982

• 7) Lands AM, Arnold A, McAuliff JP et al:Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597-598, 1967
  pubmed

• 8) Moen MD, Wagstaff AJ:Nebivolol:a review of its use in the management of hypertension and chronic heart failure. Drugs 66:1389-1409, 2006
  pubmed

• 9) Mancia G, De Baker G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007

• 10) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975

• 11) Clifton JE, Collins I, Hallett P et al:Arylethanolamines derived from salicylamide with α-and β-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides. J Med Chem 25:670-679, 1982

• 12) Palazzuoli A, Calabria P, Versuri MS et al:Carvedilol:something else than a simple β-blocker? Eur Rev Med Pharmacol Sci 6:115-126, 2002

• 13) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 14) Torp-Pedersen C, Metra M, Chalesworth A et al; COMET investigators:Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure:data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 93:968-973, 2007
  pubmed

• 15) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005

• 16) Australia-New Zealand Heart Failure Research Collaborative Group:Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92:212-218, 1995

• 17) Cucherat M:Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction:ameta-regression of randomized clinical trials. Eur Heart J 28:3012-3019, 2007

• 18) Flannery G, Gehrig-Mills R, Billah B et al:Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving β-blockers. Am J Cardiol 101:865-869, 2008

• 19) Israili ZH, Hernandez-Hernandez R, Valasco M:The future of antihypertensive treatment. Am J Ther 14:121-134, 2007
  pubmed

• 20) 築山久一郎, 小林俊一, 峰岸慎太郎:高血圧から慢性心不全までの大規模介入試験からみたβ遮断薬の評価. Ther Res 29:9-32, 2008

P.39 掲載の参考文献

• 1) Prichard BNC:The second Lilly Prize Lecture, University of Newcastle, July 1977. β-adrenergic receptor blockade in hypertension, past, present, and future. Br J Clin Pharmacol 5:379-399, 1978

• 2) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 3) CIBIS-II investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBISII):a randomised trial. Lancet 353:9-13, 1999

• 4) Packer M, Bristow MR, Cohn JN et al;The U.S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1335, 1996

• 5) Packer M, Coats AJS, Fowler MB et al;Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 6) The CAPRICORN investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomized trial. Lancet 357:1385-1390, 2001
  pubmed

• 7) Hori M, Sasayama S, Kitabatake A et al; MUCHA Investigators:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

• 8) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975

• 9) Bakris GL, Fonseca V, Katholi RE et al:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

P.45 掲載の参考文献

• 1) Hoffmann C, Leitz MR, Oberdorf-Maass S et al:Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 369:151-159, 2004

• 2) Baker JG:The selectivity ofβ-adrenoreceptor antagonists at the human β1, β2 andβ3 adrenoceptors. Br J Pharmacol 144:317-322, 2005

• 3) Molenaar P, Chen L, Semmler AB et al:Human heart β-adrenoceptors:β1-adrenoceptor diversification through`affinity states' and polymorphism. Clin Exp Pharmacol Physiol 34:1020-1028, 2007

• 4) Lohse MJ, Engelhardt S, Eschenhagen T:What is the role of β-adrenergic signaling in heart failure? Circ Res 93:896-906, 2003

• 5) Noma T, Lemaire A, Naga Prasad SV et al:β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458, 2007

• 6) Kim IM, Tilley DG, Chen J et al:β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 105:14555-14560, 2008

• 7) 坂本篤裕:ランジオロール (オノアクト(R)50注) . 臨麻 26:2002

Part 2 β遮断薬に関する最近の話題

P.53 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009

• 2) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:a meta-analysis. Lancet 358:1305-1315, 2001
  pubmed

• 3) Bangalore S, Sawhney S, Messerli FH:Relation of β-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52:1482-1489, 2008

• 4) Bangalore S, Wild D, Parkar S et al:β-Blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 52:1062-1072, 2008

• 5) 日本循環器学会:心筋梗塞二次予防に関するガイドライン (2006年改訂版) . 循環器病の診断と治療に関するガイドライン (2004-2005年度合同研究班報告) <http://www.j-circ.or.jp/guideline/pdf/JCS2006_ishikawa_h.pdf>

• 6) 日本循環器学会:急性心筋梗塞 (ST上昇型) の診療に関するガイドライン:循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告). Jpn Circ J 72 (Suppl IV):S1347-S1442, 2008

• 7) 日本循環器学会:冠攣縮性狭心症の診断と治療に関するガイドライン:循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告). Jpn Circ J 72 (Suppl IV), S1195-S1238, 2008

• 8) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 9) Willenheimer R, van Veldhuisen DJ, Silke B et al; CIBIS III Investigators:Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112:2426-2435, 2005
  pubmed

• 10) 日本循環器学会:慢性心不全治療ガイドライン:循環器病の診断と治療に関するガイドライン (2004年度合同研究班報告) <http://www.j-circ.or.jp/guideline/pdf/JCS2005_matsuzaki_h.pdf>

• 11) Hori M, Sasayama S, Kitabatake A et al:MUCHA Investigators:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

• 12) 日本循環器学会:不整脈薬物治療に関するガイドライン:循環器病の診断と治療に関するガイドライン (2002-2003年度合同研究班報告). Circ J 68 (Supple IV):981-1053, 2004

P.60 掲載の参考文献

• 1) Dzau VJ, Braunwald E:Resolved and unresolved issues in the prevention and treatment of coronary artery disease:a workshop consensus statement. Am Heart J 121:1244-1263, 1991

• 2) Dzau VJ, Antman EM, Black HR et al:The cardiovascular disease continuum validated:Clinical evidence of improved patient outcomes:part I:Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 114:2850-2870, 2006
  pubmed

• 3) Mochizuki M, Yano M, Oda T et al:Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49:1722-1732, 2007
  pubmed

• 4) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
  pubmed

• 5) Wikstrand J, Warnold I, Tuomilehto J et al:Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 17:579-588, 1991
  pubmed

• 6) Bakris GL, Fonseca V, Katholi RE et al:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 7) Cucherat M, Boissel JP, Leizorovicz A;APSI Investigators:Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. Am J Cardiol 79:587-589, 1997
  pubmed

• 8) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 9) Doughty RN, Whalley GA, Walsh HA et al; CAPRICORN Echo Substudy Investigators:Effects of carvedilol on left ventricular remodeling after acute myocardial infarction:the CAPRICORN Echo Substudy. Circulation 109:201-206, 2004
  pubmed

• 10) Hori M, Sasayama S, Kitabatake A et al; MUCHA Investigators:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

• 11) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996

• 12) β-Blocker Evaluation of Survival Trial Investigators:A trial of theβ-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001

• 13) Ronco C, Haapio M, House AA et al:Cardiorenal syndrome. J Am Coll Cardiol 52:1527-1539, 2008
  pubmed

• 14) Hillege HL, Nitsch D, Pfeffer MA et al; Candesartan in Heart Failure:Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators:Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671-678, 2006

• 15) Cice G, Ferrara L, D' Andrea A et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:a prospective, placebo controlled trial. J Am Coll Cardiol 41:1438-1444, 2003

• 16) Abbott KC, Trespalacios FC, Agodoa LY et al:β-Blocker use in long-term dialysis patients:association with hospitalized heart failure and mortality. Arch Intern Med 164:2465-2471, 2004

• 17) Wright RS, Reeder GS, Herzog CA et al:Acute myocardial infarction and renal dysfunction:a high-risk combination. Ann Intern Med 137:563-570, 2002
  pubmed

• 18) Bakris GL, Hart P, Ritz E:β Blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006

P.66 掲載の参考文献

• 1) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 2) Waagstein F, Bristow MR, Swedberg K et al; Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:Beneficial effects of metoprolol inidiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993

• 3) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
  pubmed

• 4) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 5) Packer M, Bristow MR, Cohn JN et al; U. S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 6) Packer M, Coats AJS, Fowler MB et al; Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 7) The Cardiac Insufficiency Bisoprolol Study H (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 8) The Xamoterol in Severe Heart Failure Study Group:Xamoterol in severe heart failure. Lancet 336:1-6, 1990

• 9) The Beta-Blocker Evaluation of Survival Trial Investigators:A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. Engl J Med 344:1659-1667, 2001

• 10) Flather MD, Shibata MC, Coats AJS et al;SENIORS Investigators:Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215-225, 2005
  pubmed

• 11) McMurray J:Making sense of SENIORS. Eur Heart J F26:203-206, 2005

• 12) Metra M, Giubbini R, Nodari S et al:Differential effects of β-blockers in patients with heart failure:A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102:546-551, 2000

• 13) Poole-Wilson PA, Swedberg K, Cleland JGF et al; Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomized controlled trial. Lancet 362:7-13, 2003

• 14) Bohler S, Saubadu S, Scheldewaert R et al:Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design. Arzneimittelforschung 49:311-317, 1999
  pubmed

• 15) Kaye DM, Lambert GW, Lefkovits J et al:Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23:570-578, 1994
  pubmed

• 16) Cohn J, Levine T, Oliveri M et al:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823, 1984

• 17) Azevedo ER, Kubo T, Mak S et al:Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure:differential effects on sympathetic activity. Circulation 104:2194-2199, 2001

• 18) Metra M, Dei Cas L, di Lenarda A et al:Beta-blockers in heart failure:are pharmacological differences clinically important? Heart Fail Rev 9:123-130, 2004

• 19) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blockers:Importance of ancillary properties. Prog Cardiovasc Dis 39:445-456, 1997

• 20) Freemantle N, Cleland J, Young P et al:β Blockade after myocardial infarction:systematic review and meta regression analysis. BMJ 318:1730-1737, 1999

• 21) Freemantle N, Urdahl H, Eastaugh J et al:What is the place ofβ-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis) interpretation. . Prog Cardiovasc Dis 44:243-250, 2002

• 22) Kjekshus J:Comments-Beta-blockers:Heart rate reduction:a mechanism of benefit. Eur Heart J 6:189, 1985

• 23) Williams RE:Beta blockade in the post-myocardial infarction setting:pharmacologic rationale and clinical evidence. Prev Cardiol 9:96-101, 2006
  pubmed

• 24) Jonsson G, Abdelnoor M, Mifller C et al:A comparisonof the two β-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. A single-centre, randomized study of 232 patients. Cardiology 103:148-155, 2005

• 25) Bangalore S, Messerli FH, Kostis JB et al:Cardiovascular protection using beta-blockers:a critical review of the evidence. J Am Coll Cardiol 50:563-572, 2007
  pubmed

• 26) Haas SJ, Vos T, Gilbert RE et al:Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146:848-853, 2003

• 27) Dahlof B, Sever PS, Poulter NR et al:ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
  pubmed

• 28) Dahlof B, Devereux RB, Kjeldsen SE et al:LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol Lancet 359:995-1003, 2002

• 29) Bakris GL, Fonseca V, Katholi RE et al:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 30) Torp-Pedersen C, Metra M, Chalesworth A et al:Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure:data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 93:968-973, 2007
  pubmed

• 31) Kaiser T, Heise T, Nosek L et al:Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 24:1397-1403, 2006
  pubmed

• 32) Bakris GL, Hart P, Rits E:Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006

• 33) Cice G, Ferrara L, D:Andrea A et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438-1444, 2003

• 34) Tomlinson B, Bompart F, Graham BR et al:Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Drugs 36 (Suppl 6):S37-S47, 1988

• 35) Marchi F, Ciriello G:Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria:a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 12:212-221, 1995
  pubmed

• 36) Bakris GL, Fonseca V, Katholi RE et al:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 37) 築山久一郎, 小林俊一, 峯岸慎太郎:高血圧から慢性心不全までの大規模介入試験からみたβ遮断薬の評価Ther Res 29:9-32, 2008

P.72 掲載の参考文献

• 1) 厚生労働省:平成18年度国民医療費の概況 <http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/06/index.html>

• 2) Turnbull F, Neal B, Algert C et al; Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003

• 3) 循環器病予防研究会:第5次循環器疾患基礎調査結果, 中央法規出版, 東京, 2003

• 4) 厚生労働省健康局総務課生活習慣病対策室:平成18年国民健康・栄養調査結果の概要, 厚生労働省, 東京, 2008, p. 31

• 5) 厚生労働省:平成18年人口動態統計の概況 <http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakuteiO6/index.html>

• 6) Chobanian AV, Bakris GL, Black HR et al:National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The JNC 7 Report. JAMA 289:2560-2572, 2003

• 7) Mancia G, De Backer G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension (ESH) ;European Society of Cardiology (ESC):2007 guidelines for the management of arterial hypertension. J Hypertens 25:1105-1187, 2007

• 8) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009

• 9) Bakris GL, Fonseca V, Katholi RE et al:GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 292:2227-2236, 2004
  pubmed

• 10) Poole-Wilson PA, Swedberg K, Cleland JGF et al:Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet 362:7-13, 2003

• 11) Goldberg RJ, Ciampa J, Lessard D et al:Long-term survival after heart failure:a contemporary population-based perspective. Arch Intern Med 167:490-496, 2007
  pubmed

• 12) Hori M, Sasayama S, Kitabatake A et al:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

• 13) Vera-Llonch M, Menzin J, Richner RE et al:Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother 35:846-851, 2001
  pubmed

• 14) Bacquet P, Levy E, McGuire A et al;CIBIS-II Investigators and Health Economics Group:Reduced costs with bisoprolol treatment for heart failure:an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-H). Eur Heart J 22:1021-1031, 2001

• 15) Caro JJ, Migliaccio-Walle K, O'Brien JA et al; MERIT-HF Study Group:Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial:a US perspective of the MERIT-HF trial. J Card Fail 11:647-656, 2005

• 16) Stewart S, McMurray JJV, Hebborn A et al;the COPERNICUS Study Group:Carvedilol reduces the costs of medical care in severe heart failure:an economic analysis of the COPERNICUS study applied to the United Kingdom. Int J Cardiol 100:143-149, 2005

• 17) Inomata T, Izumi T, Kobayashi M:Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. Cirl J 68:35-40, 2004

P.79 掲載の参考文献

• 1) The fourth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC IV). Arch Intern Med 148:1023-1038, 1988

• 2) The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153:154-183, 1993
  pubmed

• 3) The sixth report of the Joint National Committee on detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157:2413-2446, 1997

• 4) National Institute for Health and Clinical Excellence Hypertension:management of hypertension in adults in primary care (NICE clinical guideline update <http://www.nice.org.uk8/CGO3>)

• 5) 日高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009. 日本高血圧学会, 東京, 2009

• 6) Chobanian AV, Bakris GL, Black HR et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee:The JNC7 report. JAMA 289:2560-2572, 2003

• 7) World Health Organization:Prevention of cardiovascular disease:guidelines for assessment and management of total cardiovascular risk, WHO, Geneva, 2007

• 8) Khan NA, McAlister FA, Rabkin SW et al;Canadian Hypertension Education Program:The 2006 Canadian Hypertension Education Program recommendation for the management of hypertension:Part II-Therapy. Can J Cardiol 22:583-593, 2006
  pubmed

• 9) Mancia G, DeBacker G, Dominiczak A et al; Management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007

• 10) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 11) Dahlof B, Sever PS, Poulter NR et al:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
  pubmed

• 12) Lindholm LH, Carlberg B, Samuelsson O:Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005

• 13) Messerli FH, Grossman E, Goldbourt U:Are β-blockers efficacious as first-line theraphy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998

• 14) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 15) Weber MA, Bakris GL, Giles T et al:β-Blockers in the treatment of hypertension:new data, new directions. J Clin Hypertens (Greenwich) 10:234-238, 2008

• 16) Arterial hypertension. Report of a WHO expert committee. World Health Organ Tech Rep Ser 628:7-56, 1978
  pubmed

• 17) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
  pubmed

• 18) Poole-Wilson PA, Lubsen J, Kirwan BA et al; A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators:Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial):randomised controlled trial. Lancet 364:849-857, 2004
  pubmed

P.83 掲載の参考文献

• 1) Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S et al; JCARE-GENERAL Investigators:Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 71:449-454, 2007
  pubmed

• 2) Komajda M, Follath F, Swedberg K et al;Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology:The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2:treatment. Eur Heart J 24:464-474, 2003

• 3) Lainscak M, Cleland JG, Lenzen MJ et al:International variations in the treatment and co-morbidity of left ventricular systolic dysfunction:data from the EuroHeart Failure Survey. Eur J Heart Fail 9:292-299 2007
  pubmed

• 4) Shelton RJ, Rigby AS, Cleland JG et al:Effect of a community heart failure clinic on uptake of β blockers by patients with obstructive airways disease and heart failure. Heart 92:331-336, 2006

• 5) Muntwyler J, Cohen-Solal A, Freemantle N et al:Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 6:663-668, 2004
  pubmed

• 6) Krum H, Hill J, Fruhwald F et al:Tolerability of beta-blockers in elderly patients with chronic heart failure:the COLA II study. Eur J Heart Fail 8:302-307, 2006
  pubmed

• 7) 日本循環器学会:循環器病の診断と治療に関するガイドライン (2004年度合同研究班報告):慢性心不全治療ガイドライン (2005年改訂版) (ホームページ公開のみ) <http://plaza.uminacjp/~circ/guideline/JCS2005_matsuzaki_h.pdf>

• 8) Hunt SA, Abraham WT, Chin MH et al;American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society:ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation:endorsed by the Heart Rhythm Society. Circulation 112:e154-e235, 2005

• 9) Dickstein K, Cohen-Solal A, Filippatos G et al:Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology:ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388-2442, 2008

Part 3 β遮断薬の各臓器への作用を探る

P.92 掲載の参考文献

• 1) Yano M, Ikeda Y, Matsuzaki M:Altered intracellular Ca2+ handling in heart failure. J Clin Invest 115:556-564, 2005
  pubmed

• 2) Carr AN, Schmidt AG, Suzuki Y et al:Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22:4124-4135, 2002
  pubmed

• 3) Penela P, Murga C, Ribas C et al:Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res 69:46-56, 2006
  pubmed

• 4) Metaye T, Gibelin H, Perdrisot R et al:Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal 17:917-928, 2005
  pubmed

• 5) Zou Y, Komuro I, Yamazaki T et al:Both Gs and Gi proteins are critically involved in isoproterenol induced cardiomyocyte hypertrophy. J Biol Chem 274:9760-9770, 1999
  pubmed

• 6) Noma T, Lemaire A, Naga Prasad SV et al:β-Arrestinmediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458, 2007

• 7) Zhu WZ, Wang SQ, Chakir K et al:Linkage ofβ1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest 111:617-625, 2003

• 8) Patterson AJ, Zhu W, Chow A et al:Protecting the myocardium:a role for the β2 adrenergic receptor in the heart. Crit Care Med 32:1041-1048, 2004

• 9) Zhu WZ, Zheng M, Koch WJ et al:Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA, 98:1607-16122001

• 10) Engelhardt S, Bohm M, Erdmann E et al:Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions:progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 27:146-154, 1996
  pubmed

• 11) Feldman AM, Cates AE, Veazey WB et al:Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82:189-197, 1988

• 12) Neumann J, Schmitz W, Scholz H et al:Increase in myocardial Gi-proteins in heart failure. Lancet ii:936-937, 1988

• 13) Marx SO, Reiken S, Hisamatsu Y et al:PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor):defective regulation in failing hearts. Cell 101:365-376, 2000
  pubmed

• 14) El-Armouche A, Pamminger T, Ditz D et al:Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 61:87-93, 2004
  pubmed

• 15) Ungerer M, Bohm M, Elce JS et al:Altered expression ofβ-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87:454-463, 1993

• 16) Engelhardt S, Hein L, Wiesmann F et al:Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064, 1999

• 17) Bisognano JD, Weinberger HD, Bohlmeyer TJ et al:Myocardial-directed overexpression of the human β1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32:817-830, 2000

• 18) Iwase M, Bishop SP, Uechi M et al:Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS, overexpression. Circ Res 78:517-524, 1996
  pubmed

• 19) Iwase M, Uechi M, Vatner DE et al:Cardiomyopathy induced by cardiac GS α overexpression. Am J Physiol Heart Circ Physiol 272:H585-H589, 1997

• 20) Antos CL, Frey N, Marx SO et al:Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89:997-1004, 2001
  pubmed

• 21) Dorn GW H, Tepe NM, Lorenz JN et al:Low-and high-level transgenic expression ofβ2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc Natl Acad Sci USA 96:6400-6405, 1999

• 22) Bernstein D, Fajardo G, Zhao M et al:Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 289:H2441-H2449, 2005

• 23) Koch WJ, Rockman HA, Samama P et al:Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a beta ARK inhibitor. Science 268:1350-1353, 1995

• 24) Rockman HA, Choi DJ, Rahman NU et al:Receptorspecific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA 93:9954-9959, 1996

• 25) Rockman HA, Chien KR, Choi DJ et al:Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in genetargeted mice. Proc Natl Acad Sci USA 95:7000-7005, 1998

• 26) Liggett SB, Cresci S, Kelly RJ et al:AGRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med 14:510-517, 2008

• 27) Mialet Perez J, Rathz DA, Petrashevskaya NN et al:β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300-1305, 2003

• 28) Small KM, Wagoner LE, Levin AM et al:Synergistic polymorphisms of β1-and α2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135-1142, 2002

• 29) Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al:A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288-11293, 2006

• 30) Liggett SB, Wagoner LE, Craft LL et al:The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102:1534-1539, 1998

• 31) Yasumura Y, Takemura K, Sakamoto A et al:Changes in myocardial gene expression associated with β-blocker therapy in patients with chronic heart failure. J Card Fail 9:469-474, 2003

• 32) Shigeyama J, Yasumura Y, Sakamoto A et al:Increased gene expression of collagen Types I and III is inhibited by β-receptor blockade in patients with dilated cardiomyopathy. Eur Heart J 26:2698-2705, 2005

• 33) Lowes BD, Gilbert EM, Abraham WT et al:Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357-1365, 2002
  pubmed

• 34) Opie LH:Mechanisms of cardiac contraction and relaxation. In:Braunwald's Heart Disease 8th Edition, eds by Libby P, Bonow RO, Mann DL et al, W B Sounders, Philadelphia, PA, 2007, p.509-p.539

• 35) Eschenhagen T:β-adrenergic signaling in heart failure-adapt or die. Nat Med 14:485-487, 2008

• 36) 長谷川洋, 小室一成:β遮断薬の心筋に対する作用. β遮断薬のすべて第2版, 荻原俊男, 築山久一郎, 横山光宏編, 先端医学社, 東京, 2004, p.58-p.64

P.99 掲載の参考文献

• 1) Guimaraes S, Moura D:Vascular adrenoceptors:an update. Pharmacol Rev 53:319-356, 2001
  pubmed

• 2) Kaumann AJ:Four β-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci 18:70-76, 1997

• 3) Molenaar P, Sarsero D, Kaumann AJ:Proposal for the interaction of non-conventional partial agonists and catecholamines with the 'putative β4-adrencceptor' in mammalian heart. Clin Exp Pharmacol Physiol 24:647-656, 1997

• 4) Galitzky J, Langin D, Montastruc J-L et al:On the presence of a putative fourth β-adrenoceptor in human adipose tissue. Trends Pharmacol Sci 19:164-166, 1998

• 5) Granneman JG:The putative β4-adrenergic receptor is a novel state of the βradrenergic receptor. Am J Physiol Endocrinol Metab 280:E199-E202, 2001

• 6) Queen LR, Ferro A:β-adrenergic receptors and nitric oxide generation in the cardiovascular system Cell Mol Life Sci 63:1070-1083, 2006

• 7) Ritter JM:Nebivolol:endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 38 (supple 3):S13-S16, 2001

• 8) Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al:Third-generation β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux. Circulation 107:2747-2752, 2003

• 9) Intengan HD, Schiffrin EL:Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J Cardiovasc Pharmacol 35:763-768, 2000
  pubmed

• 10) Broeders MA, Doevendans PA, Bekkers BC et al:Nebivolol:a third generation β-blocker that augments vascular nitric oxide release:endothelial β2-adrenergic receptor-mediated nitric oxide production. Circulation 102:677-684, 2000

• 11) Dessy C, Saliez J, Ghisdal P et al:Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation 112:1198-1205, 2005

• 12) Dandona P, Karne R, Ghanim H et al:Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101:122-124, 2000
  pubmed

• 13) Feuerstein G, Yue TL, Ma X et al:Novel mechanisms in the treatment of heart failure:inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 41 (Suppl 1):17-24, 1988

• 14) Yasunari K, Maeda K, Nakamura M et al:Carvedilol inhibits pressure-induced increase in oxidative stress in coronary smooth muscle cells. Hypertens Res 25:419-425, 2002
  pubmed

• 15) Maggi E, Marchesi E, Covini D et al:Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 27:532-538, 1996

• 16) Yue TL, Wang X, Gu JL et al:Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 294:585-591, 1995
  pubmed

• 17) Ohlstein EH, Vickery L, Arleth A et al:Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 16:163-177, 1994
  pubmed

• 18) Ohlstein EH, Douglas SA, Sung CP et al:Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 90:6189-6193, 1993
  pubmed

• 19) Whittington-Coleman PJ, Carrier O Jr, Douglas BH:The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 18:337-345, 1973
  pubmed

• 20) Hurt E, Camejo G:Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. Atherosclerosis 67:115-126, 1987
  pubmed

• 21) Linden T, Camejo G, Wiklund O et al:Effect of short-term βblockade on serum lipid levels and on the interaction of LDL with human arterial Proteoglycans. J Clin Pharmacol 30 (Suppl 2):S124-S131, 1990

• 22) Feuerstein GZ, Fisher M, Nunnart J et al:Carvedilol inhibits aortic Upid deposition in the hypercholesterolemic rat. Pharmacology 54:24-32, 1997

• 23) Wikstrand J, Berglund G, Hedblad B et al:Antiatherosclerotic effects of β-blockers. Am J Cardiol 91 (Suppl H):S25-S29, 2003

• 24) Wikstrand J, Warnold I, Tuomilehto J et al:Metprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 17:579-588, 1991

P.104 掲載の参考文献

• 1) Coca A, Messerli FH, Benetos A et al:Predicting stroke risk in hypertensive patients with coronary artery disease:a report from the INVEST. Stroke 39:343-348, 2008

• 2) 北川一夫, 松本昌泰, 堀正二:β遮断薬の脳循環に対する作用. β遮断薬のすべて, 荻原俊男, 築山久一郎, 横山光宏編, 先端医学社, 東京, 2000, p.75-p.79

• 3) 北川一夫, 堀正二:β遮断薬の脳循環に対する作用. β遮断薬のすべて第2版, 荻原俊男, 築山久一郎, 横山光宏編, 先端医学社, 東京, 2004, p.75-p.80

• 4) Powers WJ, Zazulia AR, Videen TO et al:Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology 57:18-24, 2001
  pubmed

• 5) Koch S, Romano JG, Forteza AM et al:Rapid blood pressure reduction in acute intracerebral hemorrhage:feasibility and safety. Neurocrit Care 8:316-321, 2008
  pubmed

• 6) Immink RV, van den Born BJH, van Montfrans GA et al:Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 52:236-240, 2008
  pubmed

• 7) Belfort MA, Tooke-Miller C, Allen JC Jr et al:Labetalol decreases cerebral perfusion without negatively affecting cerebral blood flow in hypertensive gravidas. Hypertens Pregnancy 21:185-197, 2002
  pubmed

• 8) Ariff B, Zambanini A, Vamadeva S et al:Candesartan-and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 37:2381-2384, 2006
  pubmed

• 9) Goyagi T, Kimura T, Nishikawa T et al:β-adrenoreceptor antagonists attenuate brain injury after transient focal ischemia in rats. Anesth Analg 103:658-663, 2006

• 10) Strosznajder RP, Jesko H, Dziewulska J:Effect of carvedilol on neuronal survival and poly (ADPribose) polymerase activity in hippocampus after transient forebrain ischemia. Acta Neurobiol Exp (Wars) 65:137-144, 2005
  pubmed

• 11) Richter F, Mikulik O, Ebersberger A et al:Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J Cereb Blood Flow Metab 25:1225-1235, 2005

• 12) Dziedzic T, Slowik A, Pera J et al:β-blockers reduce the risk of early death in ischemic stroke. J Neurol Sci 252:53-56, 2007

• 13) Dirnagl U, Klehmet J, Braun JS et al:Stroke-induced immunodepression:experimental evidence and clinical relevance. Stroke 38:770-773, 2007
  pubmed

• 14) Prass K, Braun JS, Dirnagl U et al:Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke 37:2607-2612, 2006

• 15) Prass K, Meisel C, Hoflich C et al:Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 198:725-736, 2003
  pubmed

P.111 掲載の参考文献

• 1) Campese VM, Krol E:Neurogenic factors in renal hypertension. Curr Hypertens Rep 4:256-260, 2002
  pubmed

• 2) Campese VM, Kogosov E:Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878-882, 1995
  pubmed

• 3) Salplachta J, Bartosikova L, Necas J:Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys 21:189-195, 2002

• 4) Amann K, Ritz E:Microvascular disease-the Cinderella of uraemic heart disease. Nephrol Dial Transplant 15:1493-1503, 2000
  pubmed

• 5) Cice G, Ferrara L, D:Andrea AE et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:a prospective palcebo-controlled trial. J Am Coll Cardiol 41:1438-1444, 2003

• 6) Klein IH, Ligtenberg G, Oey PL et al:Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:2427-2433, 2001
  pubmed

• 7) Zoccali C, Mallamaci F, Parlongo S et al:Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359, 2002
  pubmed

• 8) Converse RL Jr, Jacobson TN, Toto RD et al:Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992

• 9) Hausberg M, Kosch M, Harmelink P et al:Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974-1979, 2002
  pubmed

• 10) Antman EM, Anbe DT, Armstrong PW et al:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110:588-636, 2004

• 11) Eknoyan G:On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure:a first step to improve the outcomes. Am J Kidney Dis 32 (Suppl 3):S1-S4, 1998

• 12) Foley RN, Herzog CA, Collins AJ:Blood pressure and long-term mortality in United States hemodialysis patients:USRDS Waves 3 and 4 study. Kidney Int 62:1784-1790, 2002
  pubmed

• 13) Horl MP, Horl WH:Drug therapy for hypertension in hemodialysis patients. Semin Dial 17:288-294, 2004
  pubmed

• 14) Bakris GL:Role for β-blockers in the management of diabetic kidney disease. Am J Hypertens 16:S7-S12, 2003

• 15) Abbot KC, Trespalacios FC, Agodoa LY et al:β-Blocker use in long-term dialysis patients:association with hospitalized heart failure and mortality. Arch Intern Med 164:2465-2471, 2004

• 16) Tresparacios FC, Taylor AJ, Agodoa LY et al:Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 62:1799-1805, 2002

• 17) Wright RS, Reeder GS, Herzog CA et al:Acute myocardial infarction and renal dysfunction:a high risk combination. Ann Intern Med 137:563-570, 2002
  pubmed

• 18) Ong HT:β blockers in hypertension and cardiovascular disease. BMJ 334:946-949, 2007

• 19) Abraham WT, Tsvetkova T, Lowes BD et al:Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation 98 (Suppl I):S378-S379, 1998

• 20) Komajda M, Lutiger B, Madeira H et al;CARMEN investigators and co-ordinators:Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur Heart Fail 6:467-475, 2004
  pubmed

• 21) Harnett JD, Foley RN, Kent GM et al:Congestive heart failure in dialysis patients:prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995
  pubmed

• 22) Bauer JH, Reams GP:Antihypertensive drugs. In:Brenner & Rector's the Kidney 5th ed, eds by Brenner BM, Rector FC, W B Saunders, Philadelphia, 1996, p.2331-p.2381

• 23) Bauer JH, Reams GP:The effects fo antihypertensive therapy on renal function. In:New Therapeutic Strategies for Hypertension (Perspectives on Hypertension, Vol 3), eds by Kaplan NM, Brenner BM, Laragh JH, Raven Press, New York, 1989, p.253-p.287

• 24) Bakris GL, Wilson DM, Burnett JC:The renal, forearm, and humoral responses to standing in the presence and absence of propranolol. Circulation 74:1061-1065, 1986

• 25) Haeusler G, Schliep HJ, Schelling P et al:High β1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol 8 (Suppl 11):S2-S15, 1986

• 26) Gerstein HC, Mann JF, Yi Q et al:Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
  pubmed

• 27) Ito S, Nagasawa T, Abe M et al:Strain vessel hypothesis. A viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res, in press

• 28) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005

• 29) Bakris GL, Fonseca V, Katholi RE et al:GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 30) Messerli FH, Bell DS, Fonseca V et al; GEMINI Investigators:Body weight changes with β-blocker use:results from GEMINI. Am J Med 120:610-615, 2007

• 31) Mogensen CE:Progression of nephropathy in long-term diabeteics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab 36:383-388, 1976

• 32) Holdaas H, Hartmann A, Berg KJ et al:Contrasting effects of angiotensin converting inhibitor and α1 antagonist on albuminuria in insulin-dependent diabetes mellitus patients with nephropathy. J Intern Med 237:63-71, 1995

• 33) Rachmani R, Levi Z, Slavachevsky I et al:Effect of an α-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria:a randomized cross-over study. Nephron 80:175-182, 1998

• 34) Singh D, Chander V, Chopra K:Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure. Am J Nephrol 23:415-421, 2003
  pubmed

• 35) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-blocking agents? Am J Hypertens 11:1258-1265, 1998

• 36) Javanovic D, Jovovic D, Mihailovic-Stanojevic N et al:Influence of carvedilol on chronic renal failure progession in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 63:446-453, 2005

• 37) Uehara Y, Takada S, Hirawa N et al:Vasoconstrictors and renal protection induced by β1-selective adrenoceptor antagonist bisoprolol. J Cardiovasc Pharmacol 23:897-906, 1994

• 38) Bakris GL, Hart P, Ritz E:β blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006

Part 4 β遮断薬の糖・脂質代謝への影響をみる

P.119 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009

• 2) Sawicki PT, Siebenhofer A:Betablocker treatment in diabetes mellitus. J Intern Med 250:11-17, 2001
  pubmed

• 3) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
  Medical*Online

• 4) Jonas M, Reicher-Reiss H, Boyko V et al;Bezafibrate Infarction Prevention (BIP) Study Group:Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 77:1273-1277, 1996

• 5) Lithell H, Pollare T, Berne C et al:The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. Blood Press 1:20-26, 1992
  pubmed

• 6) Lithell H, Pollare T, Vessby B:Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1:92-101, 1992

• 7) Pollare T, Lithell H, Morlin C et al:Metabolic effects of diltiazem and atenolol:results from a randomized, double-blind study with parallel groups. J Hypertens 7:551-559, 1989
  pubmed

• 8) Pollare T, Lithell H, Selinus I et al:Sensitivity to insulin during treatment with atenolol and metoprolol:a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298:1152-1157, 1989
  pubmed

• 9) Rossner S, Taylor CL, Byington RP et al:Long term propranolol treatment and changes in body weight after myocardial infarction. BMI 300:902-903, 1990

• 10) Gress TW, Nieto FJ, Shahar E et al:Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342:905-912, 2000
  pubmed

• 11) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity:the carvedilol-metoprolol study. J Hypertens 14:489-494, 1996
  pubmed

• 12) Hansson L, Lindholm LH, Niskanen L et al:Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999

• 13) Dahlof B, Devereux RB, Kjeldsen SE et al;LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002

• 14) Pepine CJ, Handberg EM, Cooper-DeHoff RM et al:A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST):a randomized controlled trial. JAMA 290:2805-2816, 2003

• 15) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
  pubmed

• 16) Malminiemi K:Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 9:295-304, 1995
  pubmed

• 17) Giugliano D, Acampora R, Marfella R et al:Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126:955-959, 1997
  pubmed

• 18) Bakris GL, Fonseca V, Katholi RE et al;GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 19) Torp-Pedersen C, Metra M, Charlesworth A et al:Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure:data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 93:968-973, 2007
  pubmed

• 20) Eggertsen R, Sivertsson R, Andren L et al:Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 1O (Suppl 11):S97-S100, 1987

P.126 掲載の参考文献

• 1) Working Group on Management of Patients with Hypertension and High Blood Cholesterol:National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 114:224-237, 1991

• 2) Frishman WH, Clark A, Johnson B:The effects of cardiovascular drugs on plasma lipids and lipoproteins. In:Cardiovascular Pharmacotherapeutics, eds by Frishman WH, Sonnenblick EH, Sica DA, McGraw-Hill, Columbus, 1997, p.1515-p1559

• 3) Mantel-Teeuwisse AK, Kloosterman JME, Maitland-van der Zee AH et al:Drug-induced lipid changes:a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 24:443-456, 2001

• 4) Bakris GL, Hart P, Ritz E:Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006
  pubmed

• 5) Kasiske BL, Ma JZ, Kalil RSN et al:Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122:133-141, 1995

• 6) Fogari R, Zoppi A, Corradi L et al:β-Blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 33:534-539, 1999

• 7) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 8) Goto Y, Tamachi H, Fusegawa Y et al:Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc Pharmacol 18 (Suppl 4):S45-S50, 1991

• 9) Sharp RP, Sirajuddin R, Sharief IM:Impact of carvedilol on the serum lipid profile. Ann Pharmacother 42:564-571, 2008
  pubmed

• 10) Hauf-Zachariou U, Widmann L, Zulsdorf B et al:A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 45:95-100, 1993
  pubmed

• 11) Malminiemi K:Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 9:295-304, 1995
  pubmed

• 12) Johnston GD, Vyssoulis G, Feely J et al:Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives:a rondomised double-blind long-term parallel group trial. J Hum Hypertens 9:123-129, 1995

• 13) 武田和夫, 篠山重威, 中川雅夫ほか:本態性高血圧症に対する血管拡張性β1遮断薬塩酸セリプロロール (セレクトール(18)錠) の長期投与における有用性と血清脂質に及ぼす影響の検討. 臨医薬 12:3161-3180, 1996

• 14) 戸塚光哉, 宮下洋, 伊藤嘉晃ほか:Celiprolol hydrochloride の脂質代謝に及ぼす影響 (特に low density lipoproteinのサイズ変化について) . 日老医誌 38:352-359, 2001

• 15) Kihara S, Kubo M, Ikeda N et al:Inhibition of purified human postheparin lipoprotein lipase by eta-adrenergic blockers in vitro. Biochem Pharmacol 38:407-411, 1989

• 16) Kubo M, Hostetler KY:Inhibition of purified bovine milk lipoprotein lipase by propranolol and other beta-adrenergic blockers in vitro. Biochem Biophys Acta 918:168-174, 1987
  pubmed

• 17) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-blocking agents? Am J Hypertens 11:1258-1265, 1998

• 18) Sharma AM, Pischon T, Hardt S et al:Hypothesis:β-tigators:Body weight changes with β-blocker use:results from GEMINI. Am J Med 120:610-615, 2007

• 19) Messerli FH, Bell DSH, Fonseca V et al;GEMINI Investigators: Body weight changes with β-blocker use: results from GEMINI. Am J Med 120: 610-615, 2007

• 20) Malminiemi K; Celiprolol Multicenter Study group:Long-term celiprolol therapy lowers fasting plasma leptin levels. Cardiovasc Drugs Ther 14:67-75, 2000
  pubmed

• 21) Yilmaz MI, Sonmez A, Caglar K et al:Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 12:147-153, 2007
  pubmed

• 22) Celik T, Iyisoy A, Kursaklioglu H et al:Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24:591-596, 2006
  pubmed

• 23) Ueshiba H, Yoshino G:Effects of celiprolol on insulin resistance and steroid hormones in essential hypertension. Ther Res 29:569-575, 2008

P.132 掲載の参考文献

• 1) Mancia G, De Backer G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 25:1105-1187, 2007

• 2) Lithell HO:Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens (Suppl) 9:S150-S154, 1996

• 3) Higashiura K, Ura N, Takada T et al:Alteration of muscles fiber composition linking to insulin resistance and hypertension in fructose-fed rats. Am J Hypertens 12:596-602, 1999 132

• 4) Togashi N, Ura N Higashiura K et al:The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18:1605-1610, 2000

• 5) Togashi N, Ura N, Higashiura K et al:Effects of TNF-α-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 39:578-580, 2002

• 6) Furuhashi M, Ura N, Higashiura K et al:Blockade of rennin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 42:76-81, 2003

• 7) Ogihara T, Nakao K, Fukui T et al; CASE-J Study Group:Clinical outcomes in hypertensive patients with high cardiovascular risks:principal results of candesartan antihypertensive survival evaluation in Japan (CASE-J) study. J Hypertens 24 (Suppl 6):30, 2006

• 8) Iimura O, Shimamoto K, Matsuda K et al:Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensive. Am J Hypertens 8:353-357, 1994

• 9) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-bloking agents? Am J Hypertens 11:1258-1265, 1998

• 10) Bakris GL, Hart P, Ritz E:β blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006

• 11) Bakris GL, Fonseca V, Katholi RE et al;GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol inpatients with type2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004

• 12) Ohtsuka T, Hamada M, Saeki H et al:Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89:996-999, 2002
  pubmed

• 13) Yasunari K, Maeda K, Nakamura M et al:Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 116:460-465, 2004
  pubmed

Part 5 β遮断薬の酸化ストレスへの効果を探る

P.137 掲載の参考文献

• 1) 廣岡良隆:"脳"と高血圧. 分子心血管病2:167-175, 2001

• 2) Dampaney RAL Polson JW, Potts PD et al:Functional organization of brain pathways subserving the baroreceptor reflex:studies in conscious animals using immediate early gene expression. Cell Mol Neurobiol 23:597-616, 2003

• 3) Peterson JR, Sharma RV, Davisson RL:Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep 8:232-241, 2006
  pubmed

• 4) 0liveira-Sales EB, Dugaich AP, Carillo BA et al:Oxidative stress contributes to renovascular hypertension. Am J Hypertens 21:98-104, 2008

• 5) Kishi T, Hiroooka Y, Kimura Y et al:Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109:2357-2362, 2004

• 6) Koga Y, Hirooka Y, Araki S:High salt intake enhances blood pressure increase during development of hypertension via oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertens Res 31:2075-2083, 2008
  pubmed

• 7) Zimmerman MC, Lazartigues E, Lang JA et al:Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91:1038-1045, 2002
  pubmed

• 8) Dai X, Cao X, Kreulen DL et al:Superoxide anion is elevated in sympathetic neurons in DOCA-salt hypertension via activation of NADPH oxidase. Am J Physiol Heart Circ 290:H1019-H1026, 2006

• 9) Remondino A, Kwon SH, Communal C et al:β-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92:136-138, 2003

• 10) Zhang GX, Kimura S, Nishiyama A et al:Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 65:230-238, 2005
  pubmed

• 11) Cargnoni A, Ceconi C, Bernocchi P et al:Reduction of oxidative stress by carvedilol:role in maintenance of ischemic myocardium viability. Cardiovasc Res 47:556-566, 2000
  pubmed

• 12) Kawai K, Qin F, Shite J et al:Importance of antioxidant and antiapoptotic effects of β-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 287:H1003-H1012, 2004

• 13) Dalla Libera L, Ravara B, Gobbo V et al:Skeletal muscle myofibrillar protein oxidation in heart failure and protective effects of carvedilol. J Mol Cell Cardiol 38:803-807, 2005
  pubmed

• 14) Flesch M, Maack C, Cremers B et al:Effects of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1OO:346-353, 1999

• 15) Gourine A, Bondar SI, Spyer KM et al:Beneficial effects of the central nervous system β-adrenoceptor blockade on the failing heart. Circ Res 102:633-636, 2008
  Medical*Online

P.144 掲載の参考文献

• 1) 金森崇, 太田成男:電子伝達とエネルギー転換系. 新ミトコンドリア学, 内海耕憧, 井上正康編, 共立出版, 東京, 2001, p.8-p.13

• 2) Ide T, Tsutsui H, Kinugawa S et al:Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 86:152-157, 2000
  pubmed

• 3) Griendling KK, Sorescu D, Ushio-Fukai M:NAD (P) H oxidase:role in cardiovascular biology and disease. Circ Res 86:494-501, 2000
  pubmed

• 4) Xiao L, Pimentel DR, Wang J et al:Role of reactive oxygen species and NAD(P)H oxidase in α1-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282:C926-C934, 2002

• 5) Berry CE, Hare JM:Xanthine oxidoreductase and cardiovascular disease:molecular mechanisms and pathophysiological implications. J Physiol 555:589-606, 2004
  pubmed

• 6) Engberding N, Spiekermann S, Schaefer A et al:Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction:a new action for an old drug? Circulation 110:2175-2179, 2004
  pubmed

• 7) Ekelund UE, Harrison RW, Shokek O et al:Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 85:437-445, 1999
  pubmed

• 8) Remondino A, Kwon SH, Communal C et al:β-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92:136-138, 2003

• 9) Zhang GX, Kimura S, Nishiyama A et al:Cardiac oxidative stress in acute and chronic isoproterenolinfused rats. Cardiovasc Res 65:230-238, 2005
  pubmed

• 10) Kim SM, Chen L, Faulhaber-Walter R et al:Regulation of renin secretion and expression in mice deficient in β1 and β2-adrenergic receptors. Hypertension 50:103-109, 2007

• 11) Siwik DA, Pagano PJ, Colucci WS:Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 280:C53-C60, 2001
  pubmed

• 12) Briest W, H61zl A, Rassler B et al:Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 52:265-273, 2001
  pubmed

• 13) Grimm D, Huber M, Jabusch HC et al:Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload:effects of beta-receptor blockade. J Mol Cell Cardiol 33:487-501, 2001
  pubmed

• 14) Senzaki H, Paolocci N, Gluzband YA et al:betablockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin n combined with evolving cardiac dysfunction. Circ Res 86:807-815, 2000

• 15) Torp-Pedersen C, Poole-Wilson PA, Swedberg K et al;COMET Investigators:Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure-COMET. Am Heart J 149:370-376, 2005
  pubmed

• 16) Communal C, Singh K, Pimentel DR et al:Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 98:1329-1334, 1998

• 17) Singh K, Xiao L, Remondino A et al:Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 189:257-265, 2001
  pubmed

• 18) Spallarossa P, Garibaldi S, Altieri P et al:Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846, 2004
  pubmed

• 19) Kukin ML, Kalman J, Charney RH et al:Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651, 1999
  pubmed

• 20) Flesch M, Maack C, Cremers B et al:Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100:346-353, 1999

• 21) Koitabashi N, Arai M, Tomaru K et al:Carvedilol effectively blocks oxidative stress-mediated downregulation of sarcoplasmic reticulum Ca2+-ATPase 2 gene transcription through modification of Spl binding. Biochem Biophys Res Commun 328:116-124, 2005

• 22) Hooper L, Ness AR, Smith GD:Antioxidant strategy for cardiovascular diseases. Lancet 357:1705-1706, 2001
  pubmed

P.150 掲載の参考文献

• 1) Belch JJ, Bridges AB, Scott N et al:Oxygen free radicals and congestive heart failure. Br Heart J65:245-248, 1991

• 2) Kono Y, Nakamura K, Kimura H et al:Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J 70:1001-1005, 2006
  pubmed

• 3) Nakamura K, Kusano K, Nakamura Y et al:Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-2871, 2002
  pubmed

• 4) Nakamura K, Kusano KF, Matsubara H et al:Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail II:117-123, 2005

• 5) Sawyer DB, Siwik DA, Xiao L et al:Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34:379-388, 2002
  pubmed

• 6) Nakamura K, Fushimi K, Kouchi H et al:Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin H. Circulation 98:794-799, 1998

• 7) Kakishita M, Nakamura K, Asanuma M et al:Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type la receptor. J Cardiovasc Pharmacol 42 (Suppl 1):S67-S70, 2003

• 8) Ide T, Tsutsui H, Kinugawa S et al:Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85:357-363, 1999
  pubmed

• 9) Pimentel DR, Amin JK, Xiao L et al:Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 89:453-460, 2001
  pubmed

• 10) Treasure CB, Vita JA, Cox DA et al:Endotheliumdependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81:772-779, 1990
  pubmed

• 11) Heymes C, Bendall JK, Ratajczak P et al:Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164-2171, 2003
  pubmed

• 12) Maack C, Kartes T, Kilter H et al:Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108:1567-1574, 2003
  pubmed

• 13) Ide T, Tsutsui H, Hayashidani S et al:Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 88:529-535, 2001
  pubmed

• 14) Takimoto E, Champion HC, Li M et al:Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115:1221-1231, 2005
  pubmed

• 15) Hiroi S, Harada H, Nishi H et al:Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun 261:332-339, 1999
  pubmed

• 16) Dieterich S, Bieligk U, Beulich K et al:Gene expression of antioxidative enzymes in the human heart:increased expression of catalase in the endstage failing heart. Circulation 101:33-39, 2000
  pubmed

• 17) Kukin ML, Kalman J, Charney RH et al:Prospective, randomized comparison of effect of long-term 3. 心不全における酸化ストレスとβ遮断薬 treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651, 1999

• 18) Chin BS, Langford NJ, Nuttall SL et al:Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. Eur J Heart Fail 5:171-174, 2003
  pubmed

• 19) Holmer SR, Kaissling B, Putnik K et al:Beta-adrenergic stimulation of renin expression in vivo. J Hypertens 15:1471-1479, 1997
  pubmed

• 20) Fung JW, Yu CM, Yip G et al:Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92:406-410, 2003

• 21) Barki-Harrington L, Luttrell LM, Rockman HA:Dual inhibition ofβ-adrenergic and angiotensin n receptors by a single antagonist:afunctional role for receptor-receptor interaction in vivo. Circulation 108:1611-1618, 2003

• 22) Ohtsuka T, Hamada M, Hiasa G et al:Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37:412-417, 2001
  pubmed

• 23) Ohtsuka T, Hamada M, Saeki H et al:Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89:996-999, 2002
  pubmed

• 24) Dandona P, Karne R, Ghanim H et al:Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101:122-124, 2000
  pubmed

• 25) Kametani R, Miura T, Harada N et al:Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. Circ J 70:321-326, 2006
  pubmed

• 26) Mollnau H, Schulz E, Daiber A et al:Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. ・Arterioscler Thromb Vasc Biol 23:615-621, 2003

• 27) Oelze M, Daiber A, Brandes RP et al:Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin H-treated rats. Hypertension 48:677-684, 2006

• 28) Yue TL, Cheng HY, Lysko PG et al:Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263:92-98, 1992
  pubmed

• 29) Flesch M, Maack C, Cremers B et al:Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1OO:346-353, 1999

Part 6 高血圧治療におけるβ遮断薬の有用性を探る

P.156 掲載の参考文献

• 1) Kaplan NM:β-Adrenergic receptor blockers. In:Clinical Hypertension 7th ed, Williams & Wilkins, Baltimore, 1998, p. 205-p213

• 2) Cruickshank JM:Are we misunderstanding β-blockers. Int J Cardio 120:10-27, 2007

• 3) Niarchos AP, Laragh JH:Renin dependency of blood pressure in isolated systolic hypertension. Am J Med 77:407-414, 1984
  pubmed

• 4) Koepke JP, Jones S, DiBona GF:Hypothalamicβ2-adrenoceptor control of renal sympathetic nerve activity and urinary sodium excretion in conscious, spontaneously hypertensive rats. Circ Res 58:241-248, 1986

• 5) Boudreau G, Peronnet F, De Champlain J et al:Presynaptic effects of epinephrine on norepinephrine release from cardiac sympathetic nerves in dogs. Am J Psysiol Heart Circ Physiol 265:H205-H211, 1993

• 6) Schindler C, Dobrev D, Grossmann M et al:Mechanisms ofβ-adrenergic receptor-mediated venodilation in humans. Clin Pharmacol Ther 75:49-59, 2004

• 7) Prichard BN, Owens CW:Mode of action of β-adrenergic blocking drugs in hypertension. Clin Physiol. Biochem 8 (Suppl 2):S1-S1O, 1990

• 8) Mori H, Ukai H, Yamamoto H et al:Current status of antihypertensive prescription and associated blood Pressure control in Japan, Hypertens. Res 29:143-151, 2006
  pubmed

• 9) Dahlof B, Sever PS, Poulter NR et al;ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. 」Lancet 366:895-906, 2005

• 10) Dahlof B, Devereux RB, Kjeldsen SE et al;LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002

P.160 掲載の参考文献

• 1) Bane C, Hughes CM, Cupples ME et al:The journey to concordance for patients with hypertension:a qualitative study in primary care. Pharm World Sci 29:534-540, 2007
  pubmed

• 2) Collins R, Peto R, MacMahon S et al:Blood pressure, stroke, and coronary heart disease. Part 2, Shortterm reductions in blood pressure:overview of randomised drug trials in their epidemiological context Lancet 335:827-838, 1990
  pubmed

• 3) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:ametaanalysis. . Lancet 358:1305-1315, 2001

• 4) Lindholm LH, Carlberg B, Samuelsson O:Should βblockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005

• 5) Bradley HA, Wiysonge CS, Volmink JA et al:How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 24:2131-2141, 2006
  pubmed

• 6) Williams B, Lacy PS, Thom SM et al:Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes:principal results of the Conduit Artery Function Evaluation CAFE) study. Circulation 113:1213-1225, 2006
  pubmed

• 7) Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al:Third-generation beta-blockers stimulate nitric oxide release from endothelial cell through ATP efflux:anovel mechanism for antihypertensive action. Circulation 107:2747-2752, 2003

• 8) Barzilay JI, Davis BR, Cutler JA et al;ALLHAT Collaborative Research Group:Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment:areport from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . Arch Intern Med 166:2191-2201, 2006

• 9) Aksnes T, Kjeldsen SE Rostrup M et al:Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 50:467-473, 2007
  pubmed

• 10) Verdecchia P, Reboldi G, Angeli F et al:Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43:963-969, 2004
  pubmed

• 11) Bakris GL, Fonseca V, Katholi RE et al;GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 292:2227-2236, 2004
  pubmed

• 12) Bakris GL, Fonseca V, Katholi RE et al;GEMINI Investigators:Differential effects ofβ-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005

• 13) Messerli FH, Bell DS, Fonseca V et al;GEMINI Investigators:Body weight changes withβ-blockers use:Results from GEMINI. Am J Med 120:610-615, 2007

• 14) Bell DS, Bakris GL, McGill JB:Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab 2008, in press

P.166 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009年版 (JSH2009), 日本高血圧学会, 東京, 2009

• 2) Chobanian AV, Bakris GL, Black HR et al;National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure;National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003

• 3) Mancia G, De Backer G, Dominiczak A et al;ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension:ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25:1751-1762, 2007
  pubmed

• 4) 築山久一郎, 小林俊一, 峯岸慎太郎:State of the Art高血圧臨床研究の動向2008高血圧から慢性心不全までの大規模介入試験からみたβ遮断薬の評価. Ther Res 29:9-32, 2008

• 5) Morgan TO, Anderson AI, MacInnis RJ:ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14:241-247, 2001
  pubmed

• 6) Deary AJ, Schumann AL Murfet H et al:Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 20:771-777, 2002
  pubmed

• 7) Smith SC Jr, Allen J, Blair SN et al;AHA/ACC; National Heart, Lung, and Blood Institute:AHA/ACC guidelines for secondary prevention forpatients with coronary and other atherosclerotic vascular disease:2006 update:endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363-2372, 2006

• 8) Japaneseβ-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators:Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93:969-973, 2004

• 9) 勝田洋輔, 今泉勉:β遮断薬・β遮断薬. 臨と研 80:22-26, 2003
  Medical*Online

• 10) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 11) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
  pubmed

• 12) Packer M, Bristow MR, Cohn JN et al;US. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 13) Beta-Blocker Evaluation of Survival Trial Investigators:A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001

• 14) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353 19-13, 1999

• 15) Packer M, Coats AJ, Fowler MB et al;Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 16) Poole-Wilson PA, Swedberg K, Cleland JG et al; Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

• 17) Hori M, Sasayama S, Kitabatake A et al;MUCHA Investigators:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

• 18) Lindholm LH, Ibsen H, Dahl?f B et al;LIFE Study Group:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:1004-1010, 2002

• 19) Dahl?f B, Sever PS, Poulter NR et al;ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005

• 20) McFarlane SI, Sowers JR:Treatment of diabetes and hypertension. In:Hypertension Primer:The Essentials of High Blood Pressure 3rd Ed, eds by Izzo JL, Black HR, Lippincott Williams & Wilkins, Philadelphia, 2003, p. 488-p. 491

• 21) Hansson L, Zanchetti A, Carruthers SG et al;HOT Study Group:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998

• 22) UK Prospective Diabetes Study Group:Efficacy of atenolol and captoprn in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. Br Med J 317:713-720, 1998

• 23) Wikstrand J, Warnold I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988
  pubmed

• 24) Messerli FH, Grossman E, Goldbourt U:Are betablockers efficacious as first-line therapy for hypertension in the elderly?Asystematic review. JAMA 279:1903-1907, 1998

P.173 掲載の参考文献

• 1) Brenner BM, Cooper ME, de Zeeuw D et al; RENAAL Study Investigators:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001

• 2) Parving HH, Lehnert H, Brochner-Mortensen J et al; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001

• 3) Lewis EJ, Hunsicker LG, Clarke WR et al:Collaborative Study Group:Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001

• 4) Dahlof B, Devereux RB, Kjeldsen SE et al:LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002

• 5) Abe M, Mori K, Nagai K et al:Relapse of Graves:disease in a patient with pheochromocytoma. Endocr J 50:767-770, 2003

• 6) Suzuki H, Moriwaki K, Kanno Y et al:Comparison of the effects of an ACE inhibitor and αβblocker on the progression of renal failure with left ventricular hypertrophy:preliminary report. Hypertens, Res 24:153-158, 2001

• 7) Suzuki H, Nakamoto H, Nemoto H et al:Control of blood pressure and prevention of end-organ damage in patients with accelerated hypertension by combination with arotinolol and extended release nifedipine. Hypertens Res 23:159-166, 2000
  pubmed

• 8) Nakamoto H, Nemoto H, Sugahara S et al:Nifedipine and arotinolol in combination for acceleratedmalignant hypertension:results of one year followup. Hypertens Res 22:75-80, 1999
  pubmed

• 9) Kuwajima I, Suzuki Y, Otsuka K et al:Effects of α, β-blocker, arotinolol chloride, on 24-h blood pressure-difference between elderly and younger hypertensive patients. J Clin Pharm Ther 18:275-280, 1993

• 10) van Zwieten PA:An overview of the pharmacodynamic properties and therapeutic potential of combined α-andβ-adrenoceptor antagonists. Drugs 45:509-517, 1993

• 11) Sica DA, Black HR:Pharmacologic considerations in the positioning ofβ-blockers in antihypertensive therapy. Curr Hypertens Rep 10:330-335, 2008

• 12)Kveiborg B, Major-Petersen A, Christiansen B et al:Carvedilol in the treatment of chronic heart failure:lessons from the Carvedilol Or Metoprolol European Trial. Vasc. Health Risk Manag 3:31-37, 2007
  pubmed

• 13) Bakris GL, Hart P, Ritz E:βblockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006

• 14) Wagoner LE, Starling RC, O:Connor CM:Cardiac function and heart failure. J Am Coll Cardiol 47 (11 Suppl):D18-D22, 2006

• 15) Stroe AF, Gheorghiade M:Carvedilol:β-blockade and beyond. Rev Cardiovasc Med 5 (Suppl 1):S18-S27, 2004

• 16) Messerli FH, Grossman E:β-blockers in hypertension:is carvedilol different? Am J Cardiol 93 (9A):7B-12B, 2004

• 17) Dulin B, Abraham WT:Pharmacology of carvedilol. Am J Cardiol 93 (9A):3B-6B, 2004
  pubmed

• 18) Agodoa LY, Appel L, Bakris GL et al;African American Study of Kidney Disease and Hypertension (AASK) Study Group:Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis:a randomized controlled trial. JAMA 285:2719-2728, 2001

• 19) Welten GM, Chonchol M, Hoeks SE et al:β-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. Kidney Int 72:1527-1534, 2007

• 20) Suzuki H:Association between β-blocker use and reduced mortality after vascular surgery in patients with kidney disease. Nat Clin Pract Nephrol 4:128-129, 2008

• 21) Balamuthusamy S, Srinivasan L Verma M et al:Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria:ameta-analysis. Am Heart J 155:791-805, 2008

• 22) Zeltner R, Poliak R, Stiasny B et al:Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol dial Transplant 23:573-579, 2008
  pubmed

• 23) Norris K, Bourgoigne J, Gassman J et al:AASK Study Group:Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48:739-751, 2006

• 24) Thornley-Brown D, Wang X, Wright JT Jr et al:Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med 166:797-805, 2006
  pubmed

• 25) Bakris GL:Role forβ-blockers in the management of diabetic kidney disease. Am J Hypertens 16:7S-12S, 2003

• 26) 大石誠一, 佐々木雅人, 森岡由紀:αβ受容体遮断薬 (YM-09538) による褐色細胞腫の治療-ラベタロールおよびブナゾシンとの比較. 臨と研 64:2274-2250, 1987

• 27) 吉永馨, 荒川規矩男:褐色細胞腫21例における Labetalolの効果. ホルモンと臨 29:515-522, 1981

• 28) Geffner DL, Hershman JM:β-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 93:61-68, 1992

• 29) Reneland R, Alvarez E, Andersson PE et al:Induction of insulin resistance byβ-blockade but not ACE-inhibition:long-term treatment with atenolol or trandolapril. J Hum Hypertens 14:175-180, 2000

• 30) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-blocking agents? AM J Hypertens II:1258-1265, 1998

• 31) Kosegawa I, Inaba M, Morita T et al:Effect of the vasodilatory β-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 20:751-761, 1998

• 32) Fogari R, Zoppi A, Lazzari P et al:Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 11:753-757, 1997
  pubmed

• 33) Schneider M, Lerch M, Papiri M et al:Metabolic neutrality of combined verapamil-trandolapril treatment in contrast toβ-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 14:669-677, 1996

• 34) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with twoβ-blocking agents on insulin sensitivity:the carvedilolmetoprolol study. 1. Hypertens 14:489-494, 1996

• 35) Cooper SA et al:Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293:H2009-H2023, 2007
  pubmed

• 36) Fallo F, Della Mea P, Sonino N et al:Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 20:855-861, 2007
  pubmed

• 37) Fonseca V, Bakris GL, Bell DS et al;GEMINI Investigators:Differential effect ofβ-blocker therapy on insulin resistance as a function of insulin sensitizer use:results from GEMINI. Diabet Med 24:759-763, 2007

• 38) Kveiborg B, Christiansen B, Major-Petersen A et al:Metabolic effects ofβ-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs 6:209-217, 2006

• 39) Lardoux H, Gerard J, Blazquez G et al:Which β-blocker in pregnancy-induced hypertension? Lancet ii:1194, 1983

• 40) Magee LA, Duley L:Oralβ-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev, CDOO2863, 2003

• 41) Montan S:Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol 16:111-115, 2004
  pubmed

P.179 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009

• 2) Chobanian AV, Bakris GL, Black HR et al ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003

• 3) Ejima Y, Hasegawa Y, Sanada S et al:Characteristics of young-onset hypertension identified by targeted screening performed at a university health check-up. Hypertens Res 29:261-267, 2006

• 4) Toyama H, Hasegawa Y, Ejima Y et al:Characteristics of young-onset white coat hypertension identified by targeted screening for hypertension at a university health check-up. Hypertens Res 31:1063-1068, 2008

• 5) Brown MJ:Matching the right drug to the right patient in essential hypertension. Heart 86:113-120, 2001

• 6) 松下啓, 梅村敏:若年者高血圧の治療. 日内会誌 92:227-233, 2003

• 7) Goldstein DS:Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5:86-99, 1983
  pubmed

• 8) Mancia G, de Baker G, Dominczak A et al:Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007

• 9) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
  pubmed

• 10) Whitworth JA; World Health Organization, International Society of Hypertension Writing Group:2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983-1992, 2003
  pubmed

• 11) 守口篤, 荻原俊男:β遮断薬の降圧作用. β遮断薬のすべて (第2版), 先端医学社, 東京, 2004, p.52-p.56

• 12) Kaplan NM, Lieberman E:Treatment of hypertension. In:Drug therapy, Clinical Hypertension 4th Edition, Williams & Wilkins, Baltimore, 1986, p.180-p.272

• 13) Buhler FR, Burkart F, Lutold BE et al:Antihypertensive beta blocking action as related to renin and age:a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 36:653-669, 1975
  pubmed

P.184 掲載の参考文献

• 1) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255-3264, 1991

• 2) Dahlof B, Lindholm L, Hansson L:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
  pubmed

• 3) MRC working party:Medical Research Council trial of treatment of hypertension in older adults:principal results. BMJ 304:405-412, 1992
  pubmed

• 4) Staessen JA, Gasowski J, Wang JG et al:Risks of untreated and treated isolated systolic hypertension in the elderly:meta-analysis of outcome trials. Lancet 355:865-872, 2000
  pubmed

• 5) National Collaborating Centre for Chronic Conditions:Hypertension:management of hypertension in adults in primary care:partial update, Royal College of Physicians, London, 2006, p.1-p.94

• 6) Khan NA, Hemmelgarn B, Padwal R et al:The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension:Part 2-therapy. Can J Cardiol 23:539-550, 2007
  pubmed

• 7) Morgan TO, Anderson AI, Maclnnis RJ:ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14:241-247, 2001

• 8) Messerli FH, Grossman E, Golgbourt U:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998.

• 9) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 10) Dahlof B, Sever PS, Poulter NR et al:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
  pubmed

• 11) Lindholm LH, Carlberg B, Samuelsson O:Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005

• 12) Bangalore S, Messerli FH, Kostis JB et al:Cardiovascular protection using beta-blockers:a critical review of the evidence. J Am Coll Cardiol 50:563-572, 2007
  pubmed

• 13) Bangalore S, Sawhney S, Messerli FH:Relation of β-blocker induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52:1482-1489, 2008

• 14) Kahn N, McAlister FA:Re-examining the efficacy of β-blockers for the treatment of hypertension:a meta-analysis. Can Med Assoc J 174:1737-1742, 2006

• 15) Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003
  pubmed

• 16) Staessen JA, Wang J-G, Thijs L:Cardiovascular prevention and blood pressure reduction:a quantitative overview updated until 1 March 2003. J Hypertens 21:1055-1076, 2003
  pubmed

• 17) Staessen JA, Birkenhager WH:Evidence that new antihypertensives are superior to older drugs. Lancet 366:869-871, 2005
  pubmed

• 18) Bakris GL, Fonseca V, Katholi RE et al:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 19) Torp-Pedersen C, Metra M, Charlesworth A et al ; COMET investigators:Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure:data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 93:968-973, 2007
  pubmed

• 20) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009

• 21) Beckett NS, Peters R, Fletcher AE et al; HYVET Study Group:Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887-1898, 2008
  pubmed

P.189 掲載の参考文献

• 1) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) . Lancet 338:1281-1285, 1991
  pubmed

• 2) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
  pubmed

• 3) Pepine CJ, Handberg EM, Cooper-DeHoff RM et al:A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST):a randomized controlled trial. JAMA 290:2805-2816, 2003

• 4) Turnbull F ; Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different bloodpressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003

• 5) Dahlof B, Devereux RB, Kjeldsen SE et al:LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002

• 6) Dahlof B, Sever PS, Poulter NR et al ; ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
  pubmed

• 7) Mancia G, de Backer G, Dominiczak A et al ; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 25:1105-1187, 2007

• 8) Bakris GL, Fonseca V, Katholi RE et al ; GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:arandomized controlled trial. JAMA 292:2227-2236, 2004

• 9) Bakris GL, Fonseca V, Katholi RE et al ; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005

• 10) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009

• 11) Davies RF, Habibi H, Klinke WP et al; Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators:Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 25:619-625, 1995
  pubmed

P.195 掲載の参考文献

• 1) Bobrie G, Chatellier G, Genes N et al:Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 291:1342-1349, 2004
  pubmed

• 2) Kario K, Eguchi K, Umeda Y et al:Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Circulation 1O8:e72-e73, 2003

• 3) Ishikawa J, Kario K, Eguchi K ; J-MORE Group et al:Regular alcohol drinking is a determinant of masked morning hypertension detected by home blood pressure monitoring in medicated hypertensive patients with well-controlled clinic blood pressure:the Jichi Morning Hypertension Research (J-MORE) study. Hypertens Res 29:679-686, 2006
  pubmed

• 4) Imai Y, Nagai K, Sakuma M et al:Ambulatory blood pressure of adults in Ohasama, Japan. Hypertension 22:900-912, 1993
  pubmed

• 5) Panza JA, Epstein SE, Quyyumi AA:Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity. N Engl J Med 325:986-990, 1991

• 6) Pickering TG, Levenstein M, Walmsley P; Hypertension and Lipid Trial Study Group:Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Am J Hypertens 7:844-847, 1994

• 7) Opie LH, Gersh BJ et al:Drugs for the Heart 6th ed, WB Saunders Co, 2004

• 8) 山田裕一, 西村重敬:病態に応じた循環器薬の使い方 β遮断薬:心筋梗塞, 狭心症における使い方. medicina 43:1520-1522, 2006

• 9) Soucek M, Rihacek I, Frana P:Acomparison of the trough-to-peak ratio of cardio-selective β-blockers in patients with newly diagnosed hypertension. Blood Press Monit 11:337-342, 2006

• 10) Morgan TO, Anderson A:Different drug classes have variable effects on blood pressure depending on the time of day. Am J Hypertens 16:46-50, 2003

• 11) Bang LE, Wiinberg N, Wachtell K et al:Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. Blood Press 16:392-397, 2007
  pubmed

• 12) Sarafidis P, Bogojevic Z, Basta E et al:Comparative efficacy of two different β-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich) 10:112-118, 2008

• 13) Marfella R, Siniscalchi M, Nappo F et al:Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 18 308-318, 2005
  pubmed

• 14) Kario K, Matsui Y, Shibasaki S et al; Japan Morning Surge-1 (JMS-1) Study Group:An α-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension:the Japan Morning Surge-1 Study. J Hypertens 26:1257-1265, 2008

• 15) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血. 圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009

• 16) Mancia G, De Backer G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC):2007 Guidelines for the management of arterial hypertension. Eur Heart J 28:1462-1536, 2007

Part 7 合併症を伴った高血圧とβ遮断薬の臨床応用を探る

P.201 掲載の参考文献

• 1) Lewington S, Clarke R, Qizilbash N et al:Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002
  pubmed

• 2) Thadani U:Selection of optimal therapy for chronic stable angina. Curr Treat Options Cardiovasc Med 8:23-35, 2006
  pubmed

• 3) Cruickshank JM, Thorp JM, Zacharias FJ:Benefits and potential harm of lowering high blood pressure. Lancet 1:581-584, 1987
  pubmed

• 4) Hansson L, Zanchetti A, Carruthers SG et al ; HOT Study Group:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998

• 5) Yusuf S, Sleight P, Pogue J et al; The Heart Outcomes Prevention Evaluation Study Investigators:Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
  pubmed

• 6) Poole-Wilson PA, Lubsen J, Kirwan BA et al ; A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators:Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial):randomised controlled trial. Lancet 364:849-857, 2004
  pubmed

• 7) Hasebe N, Kido S, Ido A et al ; Angiographical Study in Angina with Hypertension Induced Insults (ASAHI) Investigators:Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res 25:381-387, 2002

• 8) Messerli FH, Mancia G, Conti CR et al:Dogma disputed:can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884-893, 2006
  pubmed

• 9) Mancia G, De Backer G, Dominiczak A et al:2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . Eur Heart J 28:1462-1536, 2007

• 10) Yasue H, Omote S, Takizawa A et al:Exertional angina pectoris caused by coronary arterial spasm:effects of various drugs. Am J Cardiol 43:647-652, 1979
  pubmed

• 11) Hippisley-Cox J, Coupland C:Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease:nested case-control analysis. BMJ 330:1059-1063, 2005
  pubmed

• 12) First International Study of Infarct Survival Collaborative Group:Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction:ISIS-1. Lancet II:57-66, 1986

• 13) Viscoli CM, Horwitz RI, Singer BH:β-Blockers after myocardial infarction:influence of first-year clinical course on long-term effectiveness. Ann Intern Med 118:99-105, 1993

• 14) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with leftventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 15) Japanese β-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators:Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93:969-973, 2004

• 16) Gillman MW, Kannel WB, Belanger A et al:Influence of heart rate on mortality among persons with hypertension:the Framingham Study. Am Heart J 125:1148-1154, 1993
  pubmed

• 17) Thomas F, Bean K, Provost JC et al:Combined effects of heart rate and pulse pressure on cardiovascular mortality according to age. J Hypertens 19:863-869, 2001

• 18) Hozawa A, Ohkubo T, Kikuya M et al:Prognostic value of home heart rate for cardiovascular mortality in the general population:the Ohasama study. Am J Hypertens 17:1005-1010, 2004
  pubmed

• 19) Diaz A, Bourassa MG, Guertin MC et al:Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967-974, 2005
  pubmed

• 20) Fox K, Ford I, Steg PG et al:Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL):a randomised, double-blind, placebo-controlled trial. Lancet 372:807-816, 2008
  pubmed

P.207 掲載の参考文献

• 1) Esler M:The sympathetic system and hypertension. Am J Hypertens 13 (suppl 1):S99-SI05, 2000

• 2) Singh BN, Courtney KR . Classification of antiarrhythmic mechanisms of drug action:experimental and clinical considerations. In:Cardiac Electrophysiology:From Cell to Bedside, eds by Zipes DP, Jalife J, W B Saunders Co, Philadelphia, 1990, p.882-p.897

• 3) Oikarinen L, Nieminen MS, Viitasalo M et al:LIFE Study Investigators:QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy:the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 43:1029-1034, 2004

• 4) McLenachan JM, Henderson E, Morris KI et al:Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 317:787-792, 1987
  pubmed

• 5) Galinier M, Balanescu S, Fourcade J et al:Prognostic value of ventricular arrhythmias in systemic hypertension.J Hypertens 15:1779-1783, 1997
  pubmed

• 6) Inoue H, Fujiki A, Origasa H et al:Prevalence of atrial fibrillation in the general population of Japan:an analysis based on periodic health examination. Int J Cardiol, 2008, in press

• 7) 不整脈薬物療法研究会:心房細動と血栓塞栓症:多施設共同調査. J Cardiol 31:227-238, 1998

• 8) Tomita F, Kohya T, Sakurai M et al:Hokkaido Atrial Fibrillation Study Group:Prevalence and clinical characteristics of patients with atrial fibrillation:analysis of 20, 000 cases in Japan. Jpn Circ J 64:653-658, 2000

• 9) Benjamin EJ, Levy D, Vaziri SM et al:Independent risk factors for atrial fibrillation in a population based cohort. The Framingham Heart Study. JAMA 271:840-844, 1994

• 10) Coumel P:Autonomic influence in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 7:999-1007, 1996
  pubmed

• 11) Okin PM, Devereux RB, Jern S et al ; Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study Investigators:Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol:the Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. Circulation 108:684-690, 2003

• 12) Wachtell K, Hornestam B, Lehto M et al:Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation:the Losartan Intervention For End point reduction in hypertension (LIFE) study. J Am Coll Cardiol 45:705-711, 2005
  pubmed

• 13) Okin PM, Wachtell K, Devereux RB et al:Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296:1242-1248, 2006
  pubmed

• 14) Hennersdorf MG, Schueller PO, Steiner S et al:Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. Hypertens Res 30:535-540, 2007
  pubmed

• 15) Why HJ, Richardson PJ:Effect of carvedilol on left ventricular function and mass in hypertension. J Cardiovasc Pharmacol 19 (Suppl 1):S50-S54, 1992

• 16) Nagele H, Bohlmann M, Eck U et al:Combination therapy with carvedilol and amiodarone in patients with severe heart failure. Eur/Heart Fail 2:71-79, 2000
  pubmed

• 17) McMurray J, Kober L, Robertson M et al:Antiarrhythmic effect of carvedilol after acute myocardial infarction:results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:525-530, 2005

• 18) Merritt JC, Niebauer M, Tarakji K et al:Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 92:735-736, 2003

• 19) Wyse DG, Waldo AL, DiMarco JP et al ; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002

• 20) van Gelder IC, Hagens VE, Bosker HA et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group:A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002

• 21) Yamashita T, Ogawa S, Aizawa Y et al ; J-RHYTHM Investigators:Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 67:738-741, 2003
  pubmed

• 22) Bayes de Luna A, Coumel P, Leclercq JF et al:Ambulatory sudden cardiac death:mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117:151-159, 1989
  pubmed

• 23) Siegel D, Black DM, Seeley DG et al:Circadian variation in ventricular arrhythmias in hypertensive men. Am J Cardiol 69:344-347, 1992
  pubmed

• 24) The Cardiac Arrhythmia Suppression Trial II Investigators:Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227-233, 1992
  pubmed

• 25) Lindholm LH, Dahlof B, Edelman JM et al:Effect of losartan on sudden cardiac death in people with diabetes:data from the LIFE study. Lancet 362:619-620, 2003
  pubmed

P.215 掲載の参考文献

• 1) DiBona G:Neural control of the kidney:past, present, and future. Hypertension 41:621-624, 2003
  pubmed

• 2) Boivin V, Jahns R, Gambaryan S et al:Immunofluorescent imaging of β1-and β2-adrenergic receptors in rat kidney. Kidney Int 59:515-531, 2001

• 3) Salomonsson M, Brannstrom K, Arendshorst WJ:α1-Adrenoceptor subtypes in rat renal resistance vessels:in vivo and in vitro studies. Am J Physiol Renal Physiol 278:F138-F147, 2000

• 4) Sato KL, do Carmo JM, Fazan VPS:Ultrastructural anatomy of the renal nerves in rats. Brain Res 1119:94-100, 2006
  pubmed

• 5) Denton KM, Shweta A, Anderson WP:Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 13:27-34, 2002
  pubmed

• 6) Denton KM, Shweta A, Flower RL et al:Predominant postglomerular vascular resistance response to reflex renal symapathetic nerve activation during ANG II clamp in rabbits. Am J Physiol Regul Integr Comp Physiol 287:R780-R786, 2004

• 7) Koomans HA, Blankestijn PJ, Joles JA:Sympathetic hyperactivity in chronic renal failure:a wake-up call. J Am Soc Nephrol 15:524-537, 2004

• 8) Satoh M, Fujimoto S, Haruna Y et al:NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288:F1144-F1152, 2005
  pubmed

• 9) Matsuguma K, Ueda S, Yamagishi S et al:Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17:2176-2183, 2006
  pubmed

• 10) Ye S, Ozgur B, Campese VM:Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51:722-727, 1997
  pubmed

• 11) Campese VM, Mitra N, Sandee D:Hypertension in renal parenchymal disease:why is it so resistant to treatment? Kidney Int 69:967-973, 2006
  pubmed

• 12) Amann K, Rump LC, Simonaviciene A et al:Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11:1469-1478, 2000
  pubmed

• 13) Bianchi S, Bigazzi R, Amoroso A et al:Silent ischemia is more prevalent among hypertensive patients with microalbuminuria and salt sensitivity. J Hum Hypertens 17:13-20, 2003
  pubmed

• 14) Ecder T, Schrier RW:Hypertension in autosomaldominant polycystic kidney disease:early occurrence and unique aspects. J Am Soc Nephrol 12:194-200, 2001
  pubmed

• 15) Vonend O, Oberhauser V, von Kugelgen I et al:ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int 61 1617-1626, 2002
  pubmed

• 16) Luippold G, Beilharz M, Muhlbauer B:Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 19:342-347, 2004

• 17) Veelken R, Vogel EM, Hilgers K et al:Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 19:1371-1378, 2008

• 18) Amann K, Nichols C, Tornig J et al:Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11:1003-1011, 1996
  pubmed

• 19) Neumann J, Ligtenberg G, Oey L et al:Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 11:2902-2907, 2004
  pubmed

• 20) Bakris GL, Hart P, Ritz E:Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006
  pubmed

• 21) Bakris GL:Role for β-blockers in the management of diabetic kidney disease. Am J Hypertens 16:S7-S12, 2003

• 22) Dupont AG:Carvedilol and the kidney. Clin Investig 70 (Suppl 1):S127-S131, 1992

• 23) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 24) Bakris GL, Fonseca V, Katholi RE et al:GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005

• 25) Marchi F, Ciriello G:Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria:a multicenter, randomized, openlabel, controlled study versus atenolol. Adv Ther 12:212-221, 1995
  pubmed

• 26) Fassbinder W, Quarder O, Waltz A:Treatment with carvedilol is associated with a significant reduction in microalbuminuria:a multicentre randomised study. Int J Clin Pract 53:519-522, 1999
  pubmed

• 27) van den Branden C, Gabriels M, Vamecq J et al:Carvedilol protects against glomerulosclerosis in rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two β-blocking drugs, carvedilol and propanolol. Nephron 77:319-324, 1997

• 28) Namikoshi T, Satoh M, Tomita N et al:Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy. Biochem Biophys Res Commun 361:835-840, 2007
  pubmed

• 29) Namikoshi T, Tomita N, Satoh M et al:Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. Hypertens Res 31:745-755, 2008
  pubmed

• 30) Ritz E, Rump LC:Do β-blockers combined with RAS inhibitors make sense after all to protect against renal injury?Curr Hypertens Rep 9:409-414, 2007

• 31) Ronco C, Haapio M, House AA et al:Cardiorenal syndrome. J Am Mardiol 52:1527-1539, 2008
  pubmed

• 32) Cice G, Ferrara L, D'Andrea A et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:aprospective, placebocontrolled trial. J Am Coll Cardiol 41:1438-1444, 2003

P.223 掲載の参考文献

• 1) 日本高血圧学会高血圧治療ガイドライン作成委員会:臓器障害を合併する高血圧:1) 脳血管障害. 高血圧治療ガイドライン2004, 日本高血圧学会, 2004, p.35-p,38

• 2) Griffith DNW, James IM, Newbury PA et al:The effect of β-adrenergic receptor blocking drugs on cerebral blood flow. Br J Clin Pharmac 7:491-494, 1979

• 3) Globus M, Keren A, Eldad M et al:The effect of chronic propranolol therapy on regional cerebral blood flow in hypertensive patients. Stroke 14:964-967, 1983

• 4) Madsen PL, Vorstrup S, Schmidt JF et al:Effect of acute and prolonged treatment with propranolol on cerebral blood flow and cerebral oxygen metabolism in healthy volunteers. Eur J Clin Pharmacol 39:295-297, 1990
  pubmed

• 5) 小原克之, 小張昌宏, 野川茂ほか:脳血管障害患者における塩酸カルテオロールの脳血流に及ぼす影響. 脳卒中 17:130-136, 1995

• 6) 田川皓一, 飯野耕三:本態性高血圧症を有する慢性脳血管障害患者の脳血流に及ぼす塩酸カルテオロール (ミケラン(R)LA) の影響. 新薬と臨 45:171-181, 1997

• 7) Kuriyama Y, Nakamura M, Kyougoku I et al:Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. Eur J Clin Pharmacol 38 (Suppl 2):S120-S121, 1990

• 8) Schmalbruch IK, Linde R, Paulson OB et al:Activation-induced resetting of cerebral metabolism and flow is abolished by β-adrenergic blockade with propranolol. Strohe 33:251-255, 2002

• 9) Coop J, Warrender TS:Randomized trial of treatment of hypertension in elderly patients in primary care. Br Med J 293:1145-1151 1986

• 10) Medical Research Council Working Party:MRC trial of treatment of mild hypertension:principal results. Br Med J 291:97-104, 1985

• 11) Wilhelmsen L, Berglund G, Elmfeldt D et al:Beta-blocker versus diuretics in hypertensive men:main results from the HAPPHY trial. J Hypertens 5:561-572, 1987

• 12) Wilkstrand J, Warnord I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988

• 13) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
  pubmed

• 14) Dahlof B, Devereux RB, Kjeldsen SE et al; LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002

• 15) Dahlof B, Sever P, Poulter N et al:ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
  pubmed

• 16) Wiysonge CSU, Bradley HA, Mayosi BM et al:Beta-blockers for hypertension. Cochrane Database Syst Rev Issue l:Art No CD002003, 2007

• 17) Lindholm LH, Carlberg B, Samuelsson O:Should β blockers remain first choice in the treatment of primary hypertension?A meta-analysis. Lancet 366:1545-1553, 2005

• 18) Staessen JA, Li Y, Thijs L et al:Blood pressure reduction and cardiovascular prevention:an update including the 2003-2004 secondary prevention trials. Hypertens Res 28:385-407, 2005
  pubmed

• 19) Sacco RL, Adams R, Albers G et al:American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology:Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack:a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke:co-sponsored by the Council on Cardiovascular Radiology and Intervention:the American Academy of Neurology affirms the value of this guideline. Stroke 37:577-617, 2006

• 20) 日本高血圧学会高血圧治療ガイドライン作成委員会:臓器障害を合併する高血圧:1) 脳血管障害. 高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009, p.46-p.49

• 21) Broderick J, Connolly S, Feldmann E et al; American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group:Guidelines for the management of spontaneous intracerebral hemorrhage in adults:2007 update:a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38:2001-2023, 2007

• 22) The Dutch TIA trial Study Group:Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 24:543-548, 1993
  pubmed

• 23) Eriksson S, Olofsson B-O, Wester P-O; TEST study group:Atenolol in secondary prevention after stroke. Cerebrovasc Dis 5:21-25, 1995

• 24) PROGRESS Collaborative Group:Randomized trial of perindopril based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
  pubmed

• 25) Schrader J, Luders S, Kulschewski A et al; MOSES Study Group:Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention:principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218-1226, 2005

• 26) Yusuf S, Diener H-C, Sacco RL et al; PRoFESS Study Group:Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225-1237, 2008

• 27) Mancia G, de Backer G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . J Hypertens 25:1105-1187, 2007

• 28) Lysko PG, Lysko KA, Yue TL et al:Neuroprotective effects of carvediol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 23:1630-1636, 1992

• 29) Saviz SL, Erhardt JA, Anthony JV et al:The novel β-blocker, carvedilol, provides neuroprotection in transient focal stroke.J Cereb Blood Flow Metab 20:1197-1204, 2000

• 30) Hedbald B, Wikstrand J, Janzon L et al:Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness:main result from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103:1721-1726, 2001

P.229 掲載の参考文献

• 1) American Diabetes Association:Treatment of hypertension in adults with diabetes. Diabetes Care 25:199-201, 2002
  pubmed

• 2) Kosegawa I, Inaba M, Morita T et al:Effects of the vasodilatory β-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 20:751-761, 1998

• 3) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with two β-blocking agents on insulin sensitivity:the carvedilolmetoprorol study. J Hypertens 14:489-494, 1996

• 4) Giugliano D, Acampora R, Marfella R et al:Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126:955-959, 1997
  pubmed

• 5) Bakris GL, Fonseca V, Katholi RE et al for the GEMINI Investigators:metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 6) Fonseca V, Bakris GL, Bell DSH et al:Differential effect of β-blocker therapy on insulin resistance as a function of insulin sensitizer use:results from GEMINI. Diabet Med 24:759-763, 2007

• 7) Shorr R, Ray WA, Daugherty JR et al:Antihypertensive and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278:40-43, 1997
  pubmed

• 9) UK Prospective Diabetes Study (UKPDS) Group:Efficacy of atenolol and captopril in reduction risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
  pubmed

• 10) Lindholm L, Ibsen H, Dahlof B et al;LIFE study group:Cardiovascular morbidity and mortality inpatients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) :a randomised trial against atenolol. Lancet 359:1004-1010, 2002

• 11) Dahlof B, Sever PS, Poulter NR et al;ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) :a multicenter randomised controlled trial. Lancet 366:895-906, 2005
  pubmed

• 12) Kjekshus J, Gilpin E, Cali G et al:Diabetic patients and β-blockers after acute myocardial infarction. Eur Heart J 11:43-50, 1990

• 13) Joans M, Reicher-Reiss H, Boyko V et al:Usefulness of β-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am j Cardiol 77:1273-1277, 1996

• 8） UK Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
  Medical*Online
  pubmed

P.235 掲載の参考文献

• 1) Dahlof B, Devereux RB, Kjeldsen SE et al ; LIFE study group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002

• 2) Dahlof B, Sever PS, Poulter NR et al ; ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
  pubmed

• 3) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009

• 4) 動脈硬化診療・疫学委員会:脂質異常症の診断基準. 動脈硬化性疾患予防ガイドライン2007年版, 日本動脈硬化学会, 東京, 2007, p.11-p.13

• 5) Kaplan JR, Manuck SB, Adams MR et al:Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 76:1364-1372, 1987
  pubmed

• 6) Oslund-Lindqvist AM, Lindqvist P, Brautigam J et al:The effect of metoprolol on diet-induced atherosclerosis in rabbits. Arteriosclerosis 8:40-45, 1988

• 7) Yue TL, Wang X, Gu JL et al:Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur/Pharmacol 294:585-591, 1995
  pubmed

• 8) Maggi E, Marchesi E, Covini D et al:Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 27:532-538, 1996

• 9) Amato M, Montorsi P, Ravani A et al:Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis:correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J 28:2094-2101, 2007

• 10) Hedblad B, Wikstrand J, Janzon L et al:Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness:main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) . Circulation 103:1721-1726, 2001

• 11) Marfella R, Siniscalchi M, Nappo F et al:Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 18:308-318, 2005
  pubmed

• 12) Sipahi I, Tuzcu EM, Wolski KE et al:β-blockers and progression of coronary atherosclerosis:pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 147:10-18, 2007

• 13) Bessho H, Suzuki J, Tobe A:Vascular effects of betaxolol, a cardioselective β-adrenoceptor antagonist in isolated rat arteries. Jpn J Pharmacol 55:351-358, 1991

• 14) Adachi T, Hori S, Miyazaki K et al:Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Eur J Pharmacol 286:201-204, 1995
  pubmed

• 15) Jayachandran M, Hayashi T, Sumi D et al:Up-regulation of endothelial nitric oxide synthase throughβ2-adrenergic receptor:the role ofβ-blocker with NO releasing action. Biochem Biophys Res Commun 280:589-594, 2001

• 16) Garlichs CD, Zhang H, MUgge A et al:Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur/Clin Invest 29:12-16, 1999
  pubmed

• 17) Ueshiba H, Yoshino G:Effects of celiprolol on insulin resistance and steroid hormones in essential hypertension. Ther Res 29:569-575, 2008

• 18) The β-Blocker Heart Attack Trial (BHAT) research group:A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707-1714, 1982

• 19) Wikstrand J, Warnold I, Tuomilehto J et al:Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17:579-588, 1991
  pubmed

• 20) Gottlieb SS, McCarter RJ, Vogel RA:Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489-497, 1998
  pubmed

• 21) Kodama K, Nishigami K, Sakamoto T et al:Tight heart rate control reduces secondary adverse events in patients with type B acute aortic dissection. Circulation 118 (14 Suppl):S167-S170, 2008

• 22) Gadowski GR, Pilcher DB, Ricci MA:Abdominal aortic aneurysm expansion rate:effect of size and beta-adrenergic blockade. J Vasc Surg 19:727-731, 1994

P.241 掲載の参考文献

• 1) 宗像正徳:高血圧の成因としての神経心理的要因の重要性はどこまでわかったか?Med Pract 21:237-239, 2004

• 2) 宗像正徳:高血圧のコントロール-ストレスとの関連 総合臨 53:547-552, 2004
  Medical*Online

• 3) 河野雄平:災害と高血圧 血圧 8:873-877, 2001
  Medical*Online

• 4) 宗像正徳:ストレスと血圧の関係は?肥満と糖尿病 3:47-49, 2004
  Medical*Online

• 5) 宗像正徳:肉体的ストレスとその昇圧に対する治療戦略. 循環器 53:207-212, 2003

• 6) 宗像正徳:レニン・アンジオテンシン系と早朝高血圧. 呼と循 53:825-832, 2005

• 7) 宗像正徳:高血圧とストレスマネジメント. 総合臨 50:160-163, 2001
  Medical*Online

• 8) 宗像正徳, 布川徹, 吉永馨ほか:精神労働と血圧. 日災医会誌 46:290-295, 1998

• 9) Munakata M, Hiraizumi T, Tomiie T et al:Psychobehavioral factors involved in the isolated office hypertension:comparison with stress-induced hypertension. J Hypertens 16:419-422, 1998
  pubmed

• 10) Munakata M, Saito Y, Nunokawa T et al:Clinical significance of blood pressure response triggered by a doctor's visit in patients with essential hypertension. Hypertens Res 25:343-349, 2002

• 11) Mattews KA, Owens JF, Kulluer LH et al:Stress-induced pulse pressure change predicts women's carotid atherosclerosis. Stroke 29:1525-1530, 1998

• 12) 宗像正徳:高血圧における「うつ」と「不安」の臨床. 自律神経 44:83-88, 2007

• 13) 宗像正徳:8. ハードな仕事は血圧も上げる? (ストレスによる高血圧) . シミュレイション内科高血圧を探る, 島田和幸編, 永井書店, 大阪, 2004, p.143-p.147

• 14) Schnall PL, Pieper C, Schwartz JE et al:The relationship between 'job strain,' workplace diastolic blood pressure, and left ventricular mass index. Results of a case-control study. JAMA 263:1929-1935, 1990
  pubmed

• 15) Parati G, Pomidossi G, Albini F et al:Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 5:93-98, 1987
  pubmed

• 16) Kikuya M, Hozawa A, Ohokubo T et al:Prognostic significance of blood pressure and heart rate variabilities:the Ohasama study. Hypertension 36:901-906, 2000
  pubmed

• 17) Hozawa A, Ohkubo T, Kikuya M et al:Prognostic value of home heart rate for cardiovascular mortality in the general population:the Ohasama study. Am J Hypertens 17:1005-1010, 2004
  pubmed

• 18) Saito K, Kim JI, Maekawa K et al:The great Hanshin-Awaji earthquake aggravates blood pressure control in treated hypertensive patients. Am J Hypertens 10:217-221, 1997
  pubmed

• 19) 宗像正徳, 布川徹, 伊藤信彦ほか:降圧治療の心理, 行動特性に及ぼす影響. 日職災医会誌 49:460-464, 2001
  Medical*Online

Part 8 虚血性心疾患治療薬としてのβ遮断薬の有用性をみる

P.249 掲載の参考文献

• 1) Amenta F, Coppola L, Gallo P et al:Autoradiographic localization of beta-adrenergic receptors in human large coronary arteries. Circ Res 68:1591-1599, 1991
  pubmed

• 2) Miyashiro JK, Feigl EO:Feedforward control of coronary blood flow via coronary beta-receptor stimulation. Circ Res 73:252-263, 1993
  pubmed

• 3) Gullestad L, Jorgensen B, Bjuro T et al:Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease. Circulation 102:987-993, 2000
  pubmed

• 4) Chilian WM:Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation 95:522-528, 1997
  pubmed

• 5) Kuo L, Chancellor JD:Adenosine potentiates flow-induced dilation of coronary arterioles by activating KATP channels in endothelium. Am J Physiol Heart Circ Physiol 269:H541-H549, 1995

• 6) Gauthier C, Leblais V, Kobzik L et al:The negative inotropic effect of β3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Ivest 102:1377-1384, 1998

• 7) Varghese P, Harrison RW, Lofthouse RA et al:β3-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 106:697-703, 2000

• 8) Yusuf S, Peto R, Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
  pubmed

• 9) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blockers:importance of ancillary properties. 1) Prog Cardiovasc Dis 39:445-456, 1997

• 10) Asanuma H, Node K, Minamino T et al:Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol 41:499-505, 2003
  pubmed

• 11) Gao F, Chen J, Lopez BL et al:Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 406:109-116, 2000

• 12) Asanuma H Minam010 T, Sanada S et al:β-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation 109:2773-2779, 2004

• 13) Antman EM, Anbe DT, Armstrong PW et al:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction) . J Am Coll Cardiol 44:e1-e211, 2004

• 14) Kernis SJ, Harjai KJ, Stone GW et al:Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 43:1773-1779, 2004
  pubmed

• 15) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 16) Pristipino C, Beltrame JF, Finocchiaro ML et al:Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circarlation 101:1102-1108, 2000
  pubmed

• 17) Japanese β-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators:Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93:969-973, 2004

• 18) Boden WE, O'Rourke RA, Teo KK et al:Optimal medical therapy with or without PCI for stable coronary disease. N Angl J Med 356:1503-1516, 2007

P.253 掲載の参考文献

• 1) First International Study of Infarct Survival Collaborative Group:Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction:ISIS-1. Lancet ii:57-66, 1986

• 2) The MIAMI Trial Research Group:Metoprolol in acute myocardial infarction (MIAMI) . A randomised placebo-controlled international trial. Eur Heart J 6:199-226, 1985

• 3) Roberts R, Rogers WJ, Mueller HS et a l:Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83:422-437, 1991

• 4) 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 8:Stabilization of the patient with acute coronary syndromes. Circulation 112 (24 Suppl):IV89-IV110, 2005

• 5) Freemantle N, Cleland J, Young P et al:βBlockade after myocardial infarction:systematic review and meta regression analysis. BMI 318:1730-1737, 1999

• 6) Chen ZM, Pan HC, Chen YP et al:COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group:Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial. Lancet 366:1622-1632, 2005

• 7) Yoshida Y, Terajima K, Sato C et al:Clinical role and efficacy of landiolol in the intensive care unit. J Anesth 22:64-69, 2008
  pubmed

• 8) 第3章 CCUの診療. CCUマニュアル, 国立循環器病センターレジデント編 中外医学社, 東京, 2000

• 9) Figueras J, Cortadellas J, Evangelista A et al:Medical management of selected patients with left ventricular free wall rupture during acute myocardial infarction. J Am Coll Cardiol 29:512-518, 1997
  pubmed

P.260 掲載の参考文献

• 1) Chadda K, Goldstein S, Byington R et al:Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 3:503-510, 1986
  pubmed

• 2) Akiyama T, Pawitan Y, Greenberg H et al; CAST Investigators:Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 68:1551-1555, 1991
  pubmed

• 3) Han J:Mechanisms of ventricular arrhythmias associated with myocardial infarction. Am J Cardiol 24:800-813, 1969
  pubmed

• 4) Clausen T, Flatman JA:β2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. Br J Pharmacol 68:749-755, 1980

• 5) Brown MJ, Brown DC, Murphy MB:Hypokalemia from β2-receptor stimulation by circulating epinephrine. N Engl J Med 309:1414-1419, 1983

• 6) Norris RM, Barnaby PE Brown MA et al:Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet ii:883-886, 1984

• 7) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 8) McMurray J, Kober L, Robertson M et al:Antiarrhythmic effect of carvedilol after acute myocardial infarction:results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:525-530, 2005

• 9) Held PH, Yusuf S:Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 14 Suppl F:18-25, 1993

• 10) Doughty RN, Whalley GA, Walsh HA et al; CAPRICORN Echo Substudy Investigators:Effects of carvedilol on left ventricular remodeling after acute myocardial infarction:the CAPRICORN Echo Substudy. Circulation 109:201-206, 2004
  pubmed

• 11) Anzai T, Yoshikawa T, Shiraki H et al:C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 96:778-784, 1997
  pubmed

• 12) Takahashi T, Anzai T, Yoshikawa T et al:Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction-role of neurohormones and cytokines. Int J Cardiol 88:257-265, 2003

• 13) Maekawa Y, Anzai T, Yoshikawa T et al:Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J Am Coll Cardiol 39:241-246, 2002
  pubmed

• 14) Anzai T, Yoshikawa T, Takahashi T et al:Earlyuse of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 99:47-53, 2003

• 15) Murray DR, Prabhu SD, Chandrasekar B:Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101:2338-2341, 2000

• 16) Burger, Benicke M, Deten A et al:Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 281:H14-H21, 2001
  pubmed

• 17) Tsutamoto T, Wada A, Maeda K et al:Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure:prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96:509-516, 1997
  pubmed

• 18) Ohtsuka T, Hamada M, Saeki H et al:Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am j Cardiol 89:996-999, 2002
  pubmed

• 19) Ogawa H, Yasue H:Comparison of the effects of beta-blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese. Jpn Circ J 67 (Supple I):15, 2003

• 20) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004
  pubmed

• 21) Naito K, Anzai T, Yoshikawa T et al:Impact of chronic kidney disease on postinfarction inflammation, oxidative stress and left ventricular remodeling. J Card Fail 14:831-838, 2008
  pubmed

• 22) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005

• 23) Bakris GL, Hart P, Ritz E:Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006
  pubmed

• 24) Cice G, Ferrara L, D'Andrea A et al:Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy:aprospective, placebocontrolled trial. J Am Coll Cardiol 41:1438-1444, 2003

P.265 掲載の参考文献

• 1) Gibbons RJ, Chatterjee K, Daley J et al:ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 33:2092-2197, 1999

• 2) van de Ven LLM, Vermeulen A, Tans JGM et al:Which drug to choose for stable angina pectoris:a comparative study between bisoprolol and nitrates. Int J Cardiol 47:217-223, 1995

• 3) de Vries RJ, van den Heuvel AF, Lok DJ et al; Netherlands Working Group on Cardiovascular Research (WCN):Nifedipine gastrointestinal therapeutic system versus atenorol in stable angina pectoris. Int J Cardiol 57:143-150, 1996

• 4) Fox KM, Mulcahy D, Findlay I et al; The TIBET Study Group:The Total Ischemic Burden European Trial (TIBET) . Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 17:96-103, 1996

• 5) Prida XE, Hill JA, Feldman RL:Systemic and coronary hemodynamic effects of combined α-and β-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am J Cardiol 59:1084-1088, 1987

• 6) 加藤和三, 飯沼宏之, 稲垣義明ほか.:血管拡張作用を有するβ遮断薬 carvedilol (DQ-2466) の狭心症に対する臨床効果-Atenolol を対象とした二重盲検比較試験-. 臨と研 67:280-293, 1996

• 7) The Japanese β-blockers and Calcium antagonists Myocardial Infarction JBCMI) Investigators:Comparison of the effect β blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93

P.269 掲載の参考文献

• 1) Cohn PF:Severe asymptomatic coronary artery disease:a diagnostic, prognostic and therapeutic puzzle. Am J Med 62:565-568, 1977
  pubmed

• 2) 戸嶋裕徳, 村山正博, 岸田浩ほか:本邦における無症候性心筋虚血の実態. 心臓 27:87-95, 1995
  Medical*Online

• 3) 津谷裕之, 三浦博:無症候性心筋虚血の病型別臨床と発生頻度および予後. 日臨 61 [増刊号5:冠動脈の臨床 (下) ]:613-620, 2003

• 4) Muller JE, Tofler GH, Stone PH:Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79:733-743, 1989
  pubmed

• 5) von Arnim T; The TIBBS Investigators:Medical treatment to reduce total ischemic burden:total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 25:231-238, 1995

• 6) Deedwania PC, Nelson JR:Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circulation 82:1296-1304, 1990
  pubmed

• 7) Stone PH, Gibson RS, Glasser SP et al; The ASIS Study Group:Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 82:1962-1972, 1990

• 8) Frishman WH, Glasser S, Stone P et al:Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 83:507-514, 1999
  pubmed

• 9) Davies RF, Habibi H, Klinke WP et al; Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators:Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 25:619-625, 1995
  pubmed

• 10) Savonitto S, Ardissiono D, Egstrup K et al:Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 27:311-316, 1996
  pubmed

• 11) Fox K, Ford I, Steg PG et al:Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):a randomised, double-blind, placebo-controlled trial. Lancet 372:807-816, 2008
  pubmed

• 12) Pepine CJ, Cohn PF, Deedwania PC et al:Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life:the Atenolol Silent Ischemia Study (ASIST) . Circulation 90:762-768, 1994
  pubmed

• 13) von Arnim T; TIBBS Investigators:Prognostic significance of transient ischemic episodes:response to treatment shows improved prognosis:results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 28:20-24, 1996

• 14) Rehnqvist N, Hjemdahl P, Billing E et al:Effects of metoprolol vs verapamil in patients with stable angina pectoris:the Angina Prognosis Study in Stockholm (APSIS) . Eur Heart J 17:76-81, 1996
  pubmed

• 15) Dargie HJ, Ford I, Fox KM; The TIBET Study Group:Total Ischaemic Burden European Trial (TIBET) . Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 17:104-112, 1996

• 16) Pristipino C, Beltrame JF, Finocchiaro ML et al:Major racial differences in coronary constrictor response between Japanese and Caucasians wit recent myocardial infarction. Circulation 101:1102-1108, 2000

P.274 掲載の参考文献

• 1) Von Hoff DD, Layard MW, Basa P et al:Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
  pubmed

• 2) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart/37:1022-1036, 1975
  pubmed

• 3) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet 353:2001-2007, 1999

• 4) CIBIS-II Investigators and Committees:The cardiac insufficiency Bisoprolol Study II (CIBIC-II):a randomised trial. Lancet 353:9-13, 1999

• 5) Packer M, Coats AJ, Fowler MB et al; Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 6) Takemura G, Fujiwara H:Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352, 2007
  pubmed

• 7) Sano M, Minamino T, Toko H et al:p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444-448, 2007
  pubmed

• 8) Liu X, Chua CC, Gao J et al:Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 286:H933-H939, 2004

• 9) Shizukuda Y, Matoba S, Mian OY et al:Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 273:25-32, 2005
  pubmed

• 10) Swain SM, Whaley FS, Ewer MS:Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials. Cancer 97:2869-2879, 2003
  pubmed

• 11) Wouters KA, Kremer LCM, Miller TL et al:Protecting against anthracycline-induced myocardial damage:areview of the most promising strategies. Br J Haematol 131:561-578, 2005

• 12) Noori A, Lindenfeld J, Wolfel E, et al:β-blockade in adriamycin-induced cardiomyopathy. J Card Fail 6:115-119, 2000

• 13) Hunt SA, Abraham WT, Chin MH et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation:endorsed by the Heart Rhythm Society:ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112:e154-e235, 2005

• 14) Kalay N, Basar E, Ozdogru I et al:Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258-2262, 6. 抗癌剤による心筋症とβ遮断薬 2006

• 15) Matsui H, Morishima I, Numaguchi Y et al:Protective effects of carvedilol against doxorubicin-induced cardiomyopathy. Life Sci 65:1265-1274, 1999
  pubmed

• 16) Spallarossa P, Garibaldi S, Altieri P et al:Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846, 2004
  pubmed

• 17) Kim IM, Tilley DG, Chen J et al:β-blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 105:14555-14560, 2008

• 18) SlamonDJ, Leyland-Jones B, Shak S et al:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783-792, 2001

• 19) Telli ML, Hunt SA, Carlson RW et al:Trastuzumab-related cardiotoxicity:calling into question the concept of reversibility. J Clin Oncol 25:3525-3533, 2007
  pubmed

• 20) Crone SA, Zhao YY, Fan L et al:ErbB2 is essential in prevention of dilated cardiomyopathy. Nat Med 8:459-465, 2002
  pubmed

• 21) Chien KR:Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 354:789-790, 2006

• 22) Guarneri V, Lenihan DJ, Valero V et al:Long-term cardiac tolerability of trastuzumab in metastatic breast cancer:the M. D. Anderson Cancer Center experience. J Clin Oncol 124:4107-4115, 2006

• 23) Suter TM, Procter M, van Veldhuisen DJ et al:Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.J Clin Oncol 25:3859-3865, 2007

• 24) Galang CK, Garcia-Ramirez J, Solski PA et al:Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-κB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transfbrmation. J Biol Chem 271:7992-7998, 1996

• 25) Murray DR, Prabhu SD, Chandrasekar B:Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101:2338-2341, 2000

• 26) Herr I, Wilhelm D, Bohler T et al:JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-α. Int J Cancer 80:417-424, 1999

• 27) Cohen MH, Gootenberg J, Keegan P et al:FDA drug approval summary:bevacizumab (Avastin R) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713-718, 2007

• 28) Izumiya Y, Shiojima I, Sato K et al:Vascular endotherial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47:887-893, 2006

Part 9 不整脈治療薬としてのβ遮断薬の臨床応用をみる

P.282 掲載の参考文献

• 1) 池田隆徳:これでわかる危険な不整脈の診かたと治療:心臓突然死を予防するノウハウを知る. 南江堂, 東京, 2008

• 2) Singh BN:Beta-blockers and calcium channel blockers as antiarrhythmic drugs. In:Cardinc Electrophysiology:from Cell to Bedside (2nd ed), eds by Zipes DP, Jalife J, Philadelphia W B Saundars, 1995, p.1317-p.1330

• 3) Lindemann JP, Watanabe AM:Sympathetic control of cardiac electrical activity. In:Cardinc Electrophysiology:From Cell to Bedside, eds by Zipes DP, Jalife J, Philadelphia, W B Saunders, 1990, p.277-p.283

• 4) Kanoupakis EM, Manios EG, Mavrakis HE et al:Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy. Cardiovasc Drugs Ther 22:169-176, 2008
  pubmed

• 5) 池田隆徳, 石黒晴久, 宮越 睦ほか:自律神経活動への影響を考慮した発作性心房細動に対する抗不整脈薬療法. Prog Med 27:970-979, 2007
  Medical*Online

• 6) Ishiguro H, Ikeda T, Abe A et al:Antiarrhythmic effect of bisoprolol, a highly selective β1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 49 281-293, 2008

• 7) McMurray J, Kober L Robertson M et al:Antiarrhythmic effect of carvedilol after acute myocardial infarction:results of the Carvedilol Post-Infarct Survival Control in Left Vennicular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:525-530, 2005

P.289 掲載の参考文献

• 1) Fuster V, Ryden LE, Asinger RW et al:ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation:executive summary:a report ofthe American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104:2118-2150, 2001

• 2) Olshansky B, Rosenfeld LE, Warner AL et al; AFFIRM Investigator s:The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study:approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43:1201-1208, 2004

• 3) Hagens VE, Rienstra M, Van Veldhuisen DJ et al:Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the Rate Control versus Electrical cardioversion (RACE) study. Am J Cardiol 98:929-932, 2006
  pubmed

• 4) 外山淳治, 三浦傅, 竹越襄ほか:心房細動治療 (薬物) ガイドライン. Jpn Circ J 65 (Suppl V):931-978, 2001

• 5) Teo KK, Yusuf S, Furberg CD:Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270:1589-1595, 1993
  pubmed

• 6) Yusuf S, Peto R, Lewis J et al:β blockade during and after myocardial infarction:an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985

• 7) Yusuf S, Wittes J, Friedman L:Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260:2088-2093, 1988
  pubmed

• 8) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet 353:2001-2007, 1999
  pubmed

• 9) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 10) Leizorovicz A, Lechat P, Cucherat M et al:Bisoprolol for the treatment of chronic heart failure:a meta-analysis on individual data of two placebocontrolled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 143:301-307, 2002
  pubmed

• 11) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996

• 12) Maggioni A:Heart Failure:treatment strategies for heart failure:β blockers and antiarrhythmics. Heart 85:97-103, 2001

• 13) Roy D, Talajic M, Nattel S et al; Atrial Fibrillation and Congestive Heart Failure Investigators:Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667-2677, 2008
  pubmed

Part 10 突然死の予防とβ遮断薬

P.295 掲載の参考文献

• 1) Myerburg RJ, Wellens HJJ:Chapter 1:epidemiology of cardiac arrest. In:Sudden Cardiac Death:a Handbook for Clinical Practice, eds by Priori SG, Zipes DP, Blackwell, Oxford, UK, 2006, p.3-p.20

• 2) Smith TW, Cain ME:Sudden cardiac death:epidemiologic and financial worldwide perspective. J Interv Card Electrophysiol 17:199-203, 2006
  pubmed

• 3) 豊島英明, 田辺直仁:1 心臓性突然死の疫学. 新不整脈学, 杉本恒明監修, 井上博編, 南江堂, 東京, 2003, p.508-p.512

• 4) Boriani G, Valzania C, Diemberger I et al:Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological preventionof sudden cardiac death. Expert Opin Investig Drugs 16:605-623, 2007

• 5) Myerburg RJ, Kessler KM, Castellanos A:Sudden cardiac death. Structure, function, and timedependence of risk. Circulation 85 (1 Suppl):I2-I10, 1992

• 6) Anderson JL, Rodier HE, Green LS:Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J cardiol 51:1196-1202, 1983
  pubmed

• 7) Dorian P:Antiarrhythmic action of β-blockers:potential mechanisms.J Cardiovasc Pharmacol Ther 10 (Suppl 1):S15-S22, 2005

• 8) Singh BN:β-adrenergic blockers as antiarrhythmic and antifibrillatory compounds:an overview. J Cardiovasc Pharmacol Ther 10 (Suppl 1):S3-S14, 2005

• 9) The Norwegian Multicenter Study Group:Timololinduced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801-807, 1981
  pubmed

• 10) The BHAT Research Group:A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 250:2814-2819, 1983

• 11) Hjalmarson A, Elmfeldt D, Herlitz J et al:Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet ii:823-827, 1981

• 12) First International Study of Infarct Survival Collaborative Group:Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarctio n:ISIS-1. Lancet ii:57-66, 1986

• 13) The MIAMI Trial Research Group:Metoprolol in acute myocardial infarction (MIAMI) . A randomised placebo-controlled international trial. Eur Heart J 6:199-226, 1985

• 14) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 15) Doughty RN, Whalley GA, Walsh HA et al; CAPRICORN Echo Substudy Investigators:Effects of carvedilol on left ventricular remodeling after acute myocardial infarction:the CAPRICORN Echo Substudy. Circulation 109:201-206, 2004
  pubmed

• 16) McMurray J, Kober L, Robertson M et al:Antiarrhythmic effect of carvedilol after acutemyocardial infarction:results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:525-530, 2005

• 17) Chen ZM, Pan HC, Chen YP et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group:Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction:randomised placebocontrolled trial. Lancet 366:1622-1632, 2005

• 18) Ellis K, Tcheng JE, Sapp S et al:Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention:pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol 16:299-305, 2003
  pubmed

• 19) Halkin A, Grines CL, Cox DA et al:Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 43:1780-1787, 2004
  pubmed

• 20) CIBIS Investigators and Committees:Arandomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation 90:1765-1773, 1994

• 21) CIBIS II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS II):a randomised trial. Lancet 353:9-13, 1999

• 22) Packer M, Bristow MR, Cohn JN et al; U.S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 23) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet 353:2001-2007, 1999

• 24) Packer M, Fowler MB, Roecker EB et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group:Effect of carvedilol on the morbidity of patients with severe chronic heart failure:results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194-2199, 2002

• 25) Poole-Wilson PA, Swedberg K, Cleland JG et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

• 26) Remme WJ, Torp-Pedersen C, Cleland JG et al:Carvedilol protects better against vascular eventsthan metoprolol in heart failure:results from COMET. J Am Coll Cardiol 49:963-971, 2007

• 27) Hori M, Sasayama S, Kitabatake A et al; MUCHA Investigators:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

Part 11 心不全治療薬としてのβ遮断薬の有用性を探る

P.304 掲載の参考文献

• 1) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
  pubmed

• 2) Cleland JGF, McGowan J, Clark A et al:The evidence for β blockers in heart failure:equals or surpasses that for angiotensin converting enzyme inhibitors. BMI 318:824-825, 1999

• 3) Pitt B, Zannad F, Remme WJ et al; Randomized Aldactone Evaluation Study Investigators:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-707, 1999
  pubmed

• 4) The SOLVD Investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
  pubmed

• 5) Pfeffer MA, Swedberg K, Granger CB et al ; CHARM Investigators and Committees:Effects of candesartan on mortality and morbidity in patients with chronic heart failure:the CHARM-Overall programme. Lancet 362:759-766, 2003
  pubmed

• 6) Remme WJ, Riegger G, Hildebrandt P et al:The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN) . Cardiovasc Drugs Ther 18:57-66, 2004

• 7) Bristow MR, Gilbert EM, Abraham WT et al ; MUCHA Investigators:Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996

• 8) Hori M, Sasayama S, Kitabatake A et al ; MUCHA Investigators:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

• 9) Bangalore S, Messerli FH, Kostis JB et al:Cardiovascular protection using beta-blocker:a critical review of the evidence. J Am Coll Cardiol 50:563-572, 2007
  pubmed

• 10) Hunt SA, Abraham WT, Chin MH et al ; American College of Cardiology:American Heart Association Task Force on Practice Guidelines ; American College of Chest Physicians ; International Society for Heart and Lung Transplantation ; Heart Rhythm Society:ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112:e154-e235, 2005

• 11) The CAPRICORN Investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 12) Dickstein K, Cohen-Solal A, Filippatos G et al; Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology; collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart j 29:2388-2442, 2008

P.308 掲載の参考文献

• 1) Cohn JN, Ferrari R, Sharpe N:Cardiac remodeling-concepts and clinical implications:a consensus paper from an international forum on cardiac remodeling. j Am Coll Cardiol 35:569-582, 2000
  pubmed

• 2) Rundqvist B, Elam M, Bergmann-Sverrisdottir Y et al:Increased cardiac adrenergic drive preceedes generalized sympathetic activation in human heart failure. Circulation 95:169-175, 1997

• 3) Floras JS:Clinical aspect of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 22 (Suppl A):72A-84A, 1993

• 4) Esler M, Kaye D, Lambert G et al:Adrenergic nervous system in heart failure. Am J Cardiol 80:7L-14L, 1997
  pubmed

• 5) Zuker IH:Novel mechanisms of sysmpathetic regulation in chronic heart failure. Hypertension 48:1005-1011, 2006

• 6) Watson AMD, Hood SG, Ramchandra R et al:Increased cardiac sympathetic nerve activity in heart failure is not due to desensitization of the arterial baroreflex. Am J Physiol Heart Circ Physiol 293:H798-H804, 2007

• 7) Badenhorst D, Veliotes D, Maseko M et al:β-Adrenergic activation initiates chamber dilatation in concentric hypertrophy. Hypertension 41:499-504, 2003

• 8) Gibbs M, Veliotes DGA, Anamourlis C et al:Chronic β-adrenoreceptor activation increases cardiaccavity size through chamber remodeling and not via modifications in myocardial material properties. Am J Physiol Heart Circ Physiol 287:H2762-H2767, 2004

• 9) Osadchii OE, Norton GR, McKechnie R et al:Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic β-adrenoreceptor activation. Am J Physiol Heart Circ Physiol 292:H1898-H1905, 2007

• 10) Bhambi B, Eghbali M:Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 139:1131-1142, 1991
  pubmed

• 11) Masson S, Arosio B, Luvara G et al:Remodeling of cardiac extracellular matrix during β-adrenergic stumulation:upregulation of SPAC in the myocardium of adult rats. J Moll Cell Cardiol 30:1505-1514, 1998

• 12) Barth W, Deten A, Bauer M et al:Differential remodeling of the left and right heart after norepinephrine treatment in rats:studies on cytokines and collagen. J Moll Cell Cardiol 32:273-284, 2000

• 13) Banfi C, Cavalca V, Veglia F et al:Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 26:481-488, 2005
  pubmed

• 14) Pfeffer MA, Lamas GA, Vaughan DE et al:Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319:80-86, 1988
  pubmed

• 15) Sharpe N, Smith H, Murphy J et al:Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting-enzyme inhibition. Lancet 337:872-876, 1991
  pubmed

• 16) Konstam MA, Rousseau MF, Kronenberg MW et al ; LVD Investigators:Effects of the angiotensin converting enzyme inhibitor enalapril on the long term progression of the left ventricular dysfunction in patients with heart failure. Circulation 86:431-438, 1992

• 17) Greenberg B, Quinones MA, Kolipillai C et al; SOLVD Investigators:Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91:2573-2581, 1995

• 18) Doughty Rn, Whalley GA, Walsh HA et al; CAPRICORN Echo Substudy Investigators:Efefcts of carvedilol on left ventricular remodeling after acute myocardial infarction:the CAPRICORN echo study. Circulation 109:201-206, 2004

• 19) Konstam MA, Rousseau MF, Kronenberg MW et al; SOLVD Investigators:Effects of the angiotensin converting enzyme inhibitor enarapril on the longterm progression of left ventricular dysfunction in patients with heart failure. Circulation 86:431-438, 1992

• 20) Wong M, Staszewsky K, Latini R et al:Valsartan benefits left ventricular structure and function in heart failure:Val-HeFT echocardiographic study. J Am Coll Cardiol 40:970-975, 2002

• 21) LeJemtel TH, Galvao M, Sonnenblick EH:Betaadrenergic blockade reverses, while ACE inhibition attenuates, left ventricular remodeling in patients with chronic heart failure. Heart Failure 14:57-63, 1998

• 22) Khattar RS, Senior R, Soman P et al:Regression of left ventricular remodeling in chronic heart failure:comparative and combined effects of captopril and carvedilol. Am Heart J 142:704-713, 2001
  pubmed

• 23) Francis GS, Cohn JN, Jhonson G et al; V-HeFT VA Cooperative Studies Group:Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 87 (suppl IV):VI40-VI48, 1993

• 24) Eichhorn EJ, Grayburn PA:β-Blocker improvement in diastolic performance:the yin and yang ventricular function changes. Am Heart J 139:584-586, 2000

• 25) Eichhorn EJ, Bedotto JB, Malloy CR et al:Effect of β-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvement in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 82:473-483, 1990

• 26) Bristow MR, Gilbert EM:Improvement in cardiac myocyte function by biological effects of medical therapy:a new concept in the treatment of heart failure. Eur Heart J 16 (suppl F):S20-S31, 1995

• 27) Eichhorn EJ, Bristow MR:Medical therapy can improve the biological properties of the chronically failing heart:a new era in the treatment of heart failure. Circulation 94:2285-2296, 1996

• 28) Eichhorn EJ:Restoring function in failing hearts:the effects of beta blockers. Am J Med 104:163-169, 1998
  pubmed

• 29) Reiken S, Wehrens XHT, Vest JA et al:β-blockers restore calcium release channel function improve cardiac muscle performance in human heart failure. Circulation 107:2459-2466, 2003

• 30) Lowes BD, Gilbert EM, Abraham WT et al:Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357-1365, 2002
  pubmed

• 31) Yasumura Y, Takemura K, Sakamoto A et al:Changes in myocardial gene expression associated with β-blocker therapy in patients with chronic heart failure. J Card Fail 9:469-474, 2003

• 32) Lechat P, Packer M, Chalon S et al:Clinical effects of β-adrenergic blockade in chronic heart failure:a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 98:1184-1191, 1998

• 33) Eichhorn EJ:Prognosis determination in heart failure. Am J Med 110 (Suppl 7A):S14-S36, 2001

• 34) Bristow MR, Gilbert EM, Abraham WT et al; MOCHA Investigators:Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996
  pubmed

• 35) Poole-Wilson PA, Swedberg K, Cleland JG et al; Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

• 36) Packer M, Antonopoulos GV, Berlin JA et al:Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure:results of a meta-analysis. Am Heart J 141:899-907, 2001
  pubmed

• 37) Metra M, Nodari S, Parrinello S et al:Marked improvement in left ventricular ejection fraction during long-term β-blockade in patients with chronic heart failure:clinical correlates and prognostic significance. Am Heart J 145:92-299, 2003

• 38) de Groote P Delour P, Mouquet F et al:The effects of β-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J 154:589-595, 2007

• 39) Ennezat PV, Ennezat CA, Vijayaraman P et al:Dissociation between improvement in left ventricular performance and functional class in patients with chronic heart failure. J Cardiovasc Pharmacol 46:262-268, 2005
  pubmed

• 40) Eichhorn EJ, Heesch CM, Risser RC et al:Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 25:154-162, 1995
  pubmed

• 41) Eichhorn EJ, Grayburn PA, Mayer SA et al:Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with β-blockade in patients with heart failure:the β-Blocker Evaluation of Survival Trial (BEST) . Circulation 108:2326-2341, 2003

• 42) Bello D, Shah DJ, Farah GM et al:Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing β-blocker therapy. Circulation 108:1945-1953, 2003

• 43) Schleman KA, Lindenfeld JA, Lowes BD et al:Predicting response to carvedilol for the treatment of heart failure:amultivariate retrospective analysis. J Card Fail 7:4-12, 2001

• 44) Arnold RH, Kotlyar E, Hayward C et al:Relation between heart rate, heart rhythm, and reverse left ventricular remodeling in response to carvedilol in patients with chronic heart failur e:a single centre, observational study. Heart 89:293-298, 2003

• 45) Eichhorn EJ, Heesch CM, Risser RC et al:Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 25:154-162, 1995
  pubmed

P.314 掲載の参考文献

• 1) Cohn JN, Levine TB, Olivari MT et al:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823, 1984
  pubmed

• 2) Bristow MR:β-adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569, 2000

• 3) Rockman HA, Chien KR, Choi DJ et al:Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the deveiopment of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 95:7000-7005, 1998

• 4) Matkovich SJ, Diwan A, Klanke JL et al:Cardiacspecific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β-adrenergic signaling. Circ. Res 99:996-1003, 2006

• 5) Yano M, Ikeda Y, Matsuzaki M:Altered intracellular Ca2+ handling in heart failure. J Clin Invest 115:556-564, 2005
  pubmed

• 6) Schmidt U, Hajjar RJ, Kim CS et al:Human heart failure:cAMP stimutaion of SR Ca2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol Heart Circ Physiol 277:H474-H480, 1999

• 7) Yano M, Kobayashi S, Kohno M et al:FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107:477-484, 2003
  pubmed

• 8) Kubo H, Margulies KB, Piacentino V III et al:Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 104:1012-1018, 2001

• 9) Gwathmey JK, Kim CS, Hajjar RJ et al:Cellular and molecular remodeling in a heart failure model treated with the β-blocker carteolol. Am J Physiol Heart Circ Physiol 276:H1678-H1690, 1999

• 10) Yano M, Ono K, Ohkusa T et al:Altered stoichiometory of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca2+leak through ryanodine receptor in heart failure. Circulation 102:2131-2136, 2000
  pubmed

• 11) Marx SO, Reiken S, Hisamatsu Y et al:PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor):defective regulation in failing hearts. Cell 101:365-376, 2000
  pubmed

• 12) Yano M, Yamamoto T, Ikeda Y et al:Mechanisms of Disease:ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Pract Cardiovasc Med 3:43-52, 2006
  pubmed

• 13) Oda T, Yano M, Yamamoto T et al:Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 111:3400-3410, 2005

• 14) Yano M, Okuda S, Oda T et al:Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 112:3633-3643, 2005
  pubmed

• 15) Reiken S, Wehrens XH, Vest JA et al:β-Blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107:2459-2466, 2003

• 16) Doi M, Yano M, Kobayashi S et al:Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 105:1374-1379, 2002
  pubmed

• 17) Mochizuki M, Yano M, Oda T et al:Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49:1722-1732, 2007
  pubmed

P.320 掲載の参考文献

• 1) Shiba N, Shimokawa H:Chronic heart failure in Japan:implications of the CHART studies. Vasc Health Risk Manag 4:103-113, 2008
  pubmed

• 2) Kannel WB, Belanger AJ:Epidemiology of heart failure. Am Heart J 121:951-957, 1991
  pubmed

• 3) Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S et al; The JCARE-CARD Investigators:Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70:1617-1623, 2006
  pubmed

• 4) 筒井裕之:高齢者心不全の実態から見た治療のあり方. 日老医誌 44:704-707, 2007

• 5) Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S et al:Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 71:449-454, 2007
  pubmed

• 6) Dulin B, Haas S, Abraham WT et al:Do elderly systolic heart failure patients benefit from β blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large scale clinical trial. Am J Cardiol 95:896-898, 2005

• 7) Aurigemma GP, Gaasch WH:Clinical practice. Diastolic heart failure. N Engl J Med 351:1097-1105, 2004
  pubmed

• 8) Mickey S:Current trends in the clinical management of an old enemy:congestive heart failure in the elderly. Am Assoc Crit Care Nurse 8:616-626, 1997

• 9) 日本循環器学会:慢性心不全治療ガイドライン (2005年改訂版) . Jpn Circ j 69:43-45, 2005

• 10) Packer M, Coats AJ, Fowler MB et al; Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severechronic heart failure. N Engl J Med 344:1651-1658, 2001

• 11) Flather M, Shibata MC, Coats AJS et al; SENIORS Investigators:Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) . Eur Heart J 26:215-225, 2005
  pubmed

• 12) Hori M, Sasayama M, Kitabatake A et al; MUCHA Investigators:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004

• 13) Pool-Wilson P, Swedberg K, Cleland JG et al:Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failurein the Carvedilol Or Metoprolol European Trial (COMET):randomized controlled trial. Lancet 362:7-13, 2004

• 14) Krum H, Hill J, Fruhwald F et al:Tolerability of β-blockers in elderly patients with chronic heart failure:the COLA II study. Eur J Heart Fail 8:302-307, 2006

• 15) Dungen HD, Apostolovic S, Inkrot S et al; CIBISELD Investigators, Subproject Multicenter Trials in the Competence Network Heart Failure:Bisoprolol vs. carvedilol in elderly patients with heart failure:rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 97:578-586, 2008
  pubmed

• 16) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial Lancet 357:1385-1390, 2001
  pubmed

• 17) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):arandomised trial. Lancet 353:9-13, 1999

P.326 掲載の参考文献

• 1) Miura K, Matsumori A, Nasermoaddeli A et al:Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan. Circ J 72:343-348, 2008
  pubmed

• 2) Kohno T, Yoshikawa T, Yoshizawa A et al:Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther 19:347-355, 2005

• 3) Rochais F, Vilardaga J, Nikolaev VO et al:Realtime optical recording of β1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 117:229-235, 2007

• 4) Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al:A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci U S A 103:11288-11293, 2006

• 5) Liggett SB, Cresci S, Kelly RJ et al:A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med 14:510-517, 2008

• 6) Nagatomo Y, Yoshikawa T, Kohno T et al:Apilot study on the role of autoantibody targeting the β1-adrenergic receptor in the response to β-blocker therapy for congestive heart failure. J Card Fail, in press

• 7) Nagatomo Y, Yoshikawa T, Kohno T et al:Effects of β-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J Card Fail 13:365-371, 2007

• 8) Tamura A, Kawano Y, Naono S et al:Relationship between β-blocker treatment and the severity of central sleep apnea in chronic heart failure. Chest 131:130-135, 2007

• 9) Kataoka M, Satoh T, Yoshikawa T et al:Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. Circ J 72:358-363, 2008
  pubmed

P.331 掲載の参考文献

• 1) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet 353:2001-2007, 1999

• 2) Bayes de Luna A, Coumel P, Leclercq JF:Ambulatory sudden cardiac death:mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117:151-159, 1989
  pubmed

• 3) Watanabe J, Shinozaki T, Shiba N:Accumulation of risk markers predicts the incidence of sudden death in patients with chronic heart failure. Eur J Heart Fail 8:237-242, 2006
  pubmed

• 4) Zipes DP, Camm AJ, Borggrefe M et al; American College of Cardiology European Heart Rhythm Association; Heart Rhythm Society; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines:ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 48:e247-e346, 2006

• 5) Bardy GH, Lee KL, Mark DB et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators:Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl Med 352:225-237, 2005

• 6) Grimm W, Christ M, Bach J et al:Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy:results of the Marburg Cardiomyopathy Study. Circulation 108:2883-2891, 2003
  pubmed

• 7) Cohn JN, Johnson G, Ziesche S et al:Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991

• 8) Naccarella F, Naccarelli GV, Maranga SS et al:Do ACE inhibitors or angiotensin n antagonists reduce total mortality and arrhythmic mortality?Acritical review of controlled clinical trials. Curr Opin Cardiol 17:6-18, 2002
  pubmed

• 9) Solomon SD, Wang D, Finn P et al:Effect of candesartan on cause-specific mortality in heart failure patients:the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 11O:2180-2183, 2004

• 10) Pitt B, Zannad F, Remme WJ et al; Randomized Aldactone Evaluation Study Investigators:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717, 1999
  pubmed

• 11) Pitt B, Remme W, Zannad F et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators:Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321, 2003

• 12) Packer M, Bristow MR, Cohn JN et al; U.S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 13) CIBIS II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 14) Packer M, Coats AJ, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
  pubmed

P.335 掲載の参考文献

• 1) Zile MR, Baicu CF, Gaasch WH:Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350:1953-1959, 2004
  pubmed

• 2) Doi R, Masuyama T, Yamamoto K et al:Development of different phenotypes of hypertensive heart failure:systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 18:111-120, 2000
  pubmed

• 3) van Heerebeek L, Borbely A, Niessen HWM et al:Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113:1966-1973, 2006
  pubmed

• 4) Masuyama T, Yamamoto K, Sakata Y et al:Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 36:2333-2338, 2000
  pubmed

• 5) Kawaguchi M, Hay I, Fetics B et al:Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction:implications for systolic and diastolic reserve limitations. Circulation 107:714-720, 2003
  pubmed

• 6) Yamamoto K, Masuyama T, Sakata Y et al:Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55:76-82, 2002

• 7) Kim MH, Devlin WH, Das SK et al:Effects of β-adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy. Circulation 10O:729-735, 1999

• 8) Yamamoto K, Nishimura RA, Chaliki HP et al:Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease:critical role of left ventricular systolic function. J Am Coll Cardiol 30:1819-1826, 1997
  pubmed

• 9) Kobayashi M, Machida N, Mitsuishi M et al:β-blocker improves survival, left ventricular function and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 17:1112-1119, 2004

• 10) Nishio M, Sakata Y, Mano T et al:Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 1O:446-453, 2008

• 11) Yancy CW, Lopatin M, Stevenson LW et al ; ADHERE Scientific Advisory Committee and Investigators:Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function:a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76-84, 2006

• 12) Dobre D, van Veldhuisen DJ, DeJongste MJ et al:Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 9:280-286, 2007
  pubmed

• 13) Flather MD, Shibata MC, Coats AJ et al ; SENIORS Investigators:Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) . Eur Heart J 26:215-225, 2005
  pubmed

• 14) Bergstrom A, Andersson B, Edner M et al:Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC) . Eur J Heart Fail 6:453-461, 2004
  pubmed

• 15) Hori M, Kitabatake A, Tsutsui H et al ; The J-DHF Program Committee:Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure:Japanese Diastolic Heart Failure Study (J-DHF) . J Card Fail 11:542-547, 2005

• 16) Nishimura RA, Schwartz RS, Holmes DR Jr et al:Failure of calcium channel blockers to improve ventricular relaxation in humans. J Am Coll Cardiol 21:182-188, 1993
  pubmed

• 17) Mulder P, Barbier S, Chagraoui A et al:Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109:1674-1679, 2004
  pubmed

• 18) Ciobotaru V, Heimburger M, Louedec L et al:Effect of long-term heart rate reduction by If current inhibition on pressure-overload-induced heart failure in rats. J Pharmacol Exp Ther 324:43-49, 2008
  pubmed

• 19) Fox K, Ford I, Steg PG et al ; BEAUTIFUL Investigators:Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):a randomised, doubleblind, placebo-controlled trial. Lancet 372:807-816, 2008
  pubmed

• 20) Fox K, Ford I, Steg PG et al:Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):a subgroup analysis of arandomised controlled trial. Lancet 372:817-821, 2008
  pubmed

• 21) DOngen HD, Apostolovic S, Inkrot S et al; CIBISELD Investigators, Subproject Multicenter Trials in the Competence Network Heart Failure:Bisoprolol vs. carvedilol in elderly patients with heart failure:rationale and design of the CIBIS-ELD trial. CLin Res Cardiol 97:578-586, 2008

P.339 掲載の参考文献

• 1) Fukunami M, Hashimura K, Ohmori M et al:Effectiveness of long-term β-blocker therapy for dilated cardiomyopathy:echocardiographical follow up. Cardiovasc Drugs Ther 5:463-469, 1991

• 2) Packer M, Antonopoulos GV, Berlin JA et al:Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure:results of a meta-analysis. Am Heart J 141:899-907, 2001
  pubmed

• 3) Di Lenarda A, Gregori D, Sinagra G et al; The Heart Muscle Disease Study Group:Metoprolol in dilated cardiomyopathy:is it possible to identify factors predictive of improvement?J Card Fail 2:87-102, 1996

• 4) de Groote P, Delour P, Mouquet F et al:The effects of β-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J 154:589-595, 2007

• 5) Yamada T, Fukunami M, Ohmori M et al:Which subgroup of patients with dilated cardiomyopathy would benefit from long-term β-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 21:628-633, 1993

• 6) Yamada T, Fukunami M, Ohmori M et al:New approach to the estimation of the extent of myocardial fibrosis in patients with dilated cardiomyopathy:use of signal averaged electrocardiography. Am Heart J 126:626-631, 1993

• 7) Yamada T, Fukunami M, Shimonagata T et al:Prediction of the effectiveness of long term β blocker treatment for dilated cardiomyopathy by signal averaged electrocardiography. Heart 79:256-261, 1998

• 8) Bello D, Shah DJ, Farah GM et al:Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing β-blocker therapy. Circulation 108:1945-1953, 2003

• 9) Eichhorn EJ, Grayburn PA, Mayer SA et al:Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with β-blockade in patients with heart failure:the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation 108:2336-2341, 2003

• 10) Ramahi TM, Longo MD, Cadariu AR et al:Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after β-blocker therapy in nonischemic cardiomyopathy. J Am Coll Cardiol 37:818-824, 2001

• 11) Richards AM, Doughty R, Nicholls MG et al:Australia-New Zealand Heart Failure Group:Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99:786-792, 1999
  pubmed

• 12) Groenning BA, Nilsson JC, Hildebrandt PR et al:Neurohumoral prediction of left-ventricular morphologic response to β-blockade with metoprolol in chronic left-ventricular systolic heart failure. Eur J Heart Fail 4:635-646, 2002

• 13) Suwa M, Otake Y, Moriguchi A et al:Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 133:353-358, 1997

• 14) Choi JY, Lee KH, Hong KP et al:Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol 8:4-9, 2001
  pubmed

P.346 掲載の参考文献

• 1) Froelicher VF, Myers J:Exercise and the heart 5th ed, W B Saunders, Philadelphia, PA, 2006

• 2) Segal JB, McNamara RL, Miller MR et al:The evidence regarding the drugs used for ventricular rate control. J Fam Pract 49:47-59, 2000
  pubmed

• 3) 松崎益徳, 相澤義房, 麻野井英次ほか:慢性心不全治療ガイドライン (2005年改訂版) . 循環器病の診断と治療に関するガイドライン (2004年度合同研究班報告) . <http://www.j-circ.or.jp/guideline/pdf/JCS2005_matsuzaki_h.pdf>

• 4) Hunt SA, Abraham WT, Chin MH et al ; American College of Cardiology ; Heart Association Task Force on Practice Guidelines ; American College of Chest Physicians ; International Society for Heart and Lung Transplantation:Heart Rhythm Society:ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation 112:154-e235, 2005

• 5) Waagstein F, Bristow MR, Swedberg K et al ; Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993

• 6) Wolfel EE, Bristow MR:Effects of long-term beta-adrenergic blockade on exercise capacity in patients with chronic heart failure. In:Exercise and Heart Failure, eds by Balady GJ, Pina IL, Futura Publishing, Armonk, NY, 1997, p.141-p.170

• 7) Vanhees L, Fagard R, Amery A:Influence of beta-adrenergic blockade on the hemodynamic effects of physical training in patients with ischemic heart disease. Am Heart J 108:270-275, 1984
  pubmed

• 8) Pavia L, Orlando G, Myers J et al:The effect of beta-blockade therapy on the response to exercise training in postmyocardial infarction patients. Clin Cardiol 18:716-720, 1995

• 9) 伊吹宗晃, 後藤葉一:長期予後改善とQOL向上をめざす心不全治療法としての運動療法. Heart View 12:554-559, 2008
  Medical*Online

• 10) 後藤葉一:心不全治療法としての心臓リハビリテーション. 心臓リハ 13:273-277, 2008
  Medical*Online

• 11) 野原隆司, 安達仁, 伊東春樹ほか:心血管疾患におけるリハビリテーションに関するガイドライン (2007 年改訂版) . 循環器病の診断と治療に関するガイドライン (2006年度合同研究班報告) . <http://www.j-circ.or.jp/guideline/pdf/JCS2007_nohara_d.pdf>

• 12) Demopoulos L, Yeh M, Gentilucci M et al:Nonselective β-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation 95:1764-1767, 1997

• 13) Forissier JF, Vernochet P, Bertrand P et al:Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure. Eur J Heart Fail 3:335-342, 2001
  pubmed

Part 12 非薬物療法とβ遮断薬

P.354 掲載の参考文献

• 1) Mangano DT:Perioperative cardiac morbidity. Anethesiology 72:153-184, 1990

• 2) Turnbull F:Blood Pressure Lowering Treatment Trialists:Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003
  pubmed

• 3) Packer M, Bristow MR, Cohn JN et al:U.S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 4) Fleisher LA, Beckman JA, Brown KA et al ; American College of Cardiology ; American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography:American Society of Nuclear Cardiology;Heart Rhythm Society:Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery:ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care noncardiac surgery. J Am Coll Cardiol 50:e159-e241, 2007

• 5) Dunning J, Treasure T, Versteegh M et al; EACTS Audit and Guidelines Committee:Guidelines on the prevention and management of the de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 30:852-872, 2006

• 6) Dodds TM, Stone JG, Coromilas J et al:Prophylactic nitroglycerin infusion during noncardiac surgery does not reduce perioperative ischemia. Anesth Analg 76:705-713, 1993

• 7) 1guchi S, lwamura H, Nishizaki M et al:Development of a highly cardioselective ultra shortacting β-blocker, ONO-1101. Chem Pharm Bull (Tokyo) 40:1462-1469, 1992

• 8) Yoshida Y, Terajima K, Sato C et al:Clinical role and efficacy of landiolol in the intensive care unit. J Anesth 22:64-69, 2008
  pubmed

• 9) Miyazaki M, Kadoi Y, Sudo T et al:Comparative effects of propofol, landiolol, and nicardipine on hemodynamic and bispectral index responses to endotracheal intubation:aprospective, randomized, double-blinded study.J Clin Anesth 20:257-262, 2008

• 10) Shirasaka T, Iwasaki T, Hosokawa N et al:Effects of landiolol on the cardiovascular respose during tracheal extubation. J Anesth 22:322-325, 2008

• 11) 南園智人, 合谷木徹, 西川俊昭:ランジオロールの抜管時における循環動態抑制効果. 臨麻 30:533-537, 2006

• 12) 藤田泰宣, 清水智明, 松本充弘ほか:未治療甲状腺機能充進症例に対する術中・術後管理における短時間作用型β遮断薬ランジオロールの有用性. 麻酔 57:1143-1146, 2008

• 13) 安部和夫, 岡淳子, 宮川繁ほか:心拍動下冠動脈バイパス術中の頻脈に対するランジオロールの効果. 循環制御 26:247-250, 2005
  Medical*Online

• 14) Sweeney MS, Frazier OH:Device-supported myocardial revascularization:safe help for sick hearts. Ann Thorac Surg 54:1065-1070, 1992
  pubmed

• 15) Omae T, Tsuneyoshi I, Higashi A et al:Ashortacting beta-blocker, landiolol, attenuates systolic anterior motion of the mitral valve after mitral annuloplasty. J Anesth 22:286-289, 2008
  pubmed

• 16) Katz AM:Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73 (Suppl III):III 184-III190, 1986

• 17) Almassi GH, Schowalter T, Nicolosi AC et al:Atrial fibrillation after cardiac surgery:amajor morbid event? Ann Surgery 226:501-511, 1997

• 18) Hogue CW Jr, Hyder ML:Atrial fibrillation after cardiac operation:risks, mechanisms, and treatment. Ann Thorac Surg 69:300-306, 2000
  pubmed

• 19) Zaman AG, Archbold RA, Helft G et al:Atrial fibrillation after coronary artery bypass surgery:a model for preoperative risk stratification. Circulation 101:1403-1408, 2000

• 20) Maisel WH, Rawn JD, Stevenson WG:Atrial fibrillation after cardiac surgery. Ann Intern Med 135:1061-1073, 2001
  pubmed

• 21) Jideus L, Blomstrom P, Nilsson L et al:Tachyarrhythmias and triggering factors for atrial fibrillation after coronary artery bypass operations. J Ann Thorac Surg 69:1064-1069, 2000

• 22) Creswell LL Schuessler RB, Rosenbloom M et al:Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 56:539-549, 1993
  pubmed

• 23) Aranki SF, Shaw DP, Adams DH et al:Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 94:390-397, 1996
  pubmed

• 24) Tsuboi J, Kawazoe K, Izumoto H et al:Postoperative treatment with carvedilol, a β-adrenergic blocker, prevets paroxysmal atrial fibrillation after coronary artery bypass grafting. Circ J 72:588-591, 2008

• 25) Gavaghan TP, Feneley MP, Campbell TJ et al:Atrial tachyarrhythmias after cardiac surgery:results of disopyramide therapy. Aust N Z J Med l 5:27-32, 1985

• 26) Asher CR, Miller DP, Grimm RA et al:Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery. Am J Cardiol 82:892-895, 1998
  pubmed

• 27) Mendes LA, Connelly GP, McKenney PA et al:Right coronary stenosis:an independent predictor of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 25:198-202, 1995
  pubmed

• 28) Eagle KA, Guyton RA, Davidoff R et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines:ACC/AHA guidelines for coronary artery bypass graft surgery:executive summary and recommendations. Circulation 1OO:1464-1480, 1999

• 29) Eagle KA, Guyton RA, Davidoff R et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery and the Society of Thoracic Surgeons:ACC/AHA 2004 guideline update for coronary artery bypass graft surgery:summary article. Circulation 110:1168-1176, 2004

• 30) Martinez EA, Epstein AE, Bass EB:Pharmacologic control of ventricular rate:American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest l28 (Suppl 1):S56-S60, 2005

• 31) Janssen J, Loomans L, Harink J et al:Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting:a randomized open trial. Angiology 37:601-609, 1986
  pubmed

• 32) Suttorp MJ, Kingma JH, Gin MTJ et al:Efficacy and safely of low-and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovasc Surg 1OO:921-926, 1990

• 33) Farshi R, Kistner D, Sarma JS et al:Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise:acrossover open-label study of five drug regimens. J Am Coll Cardiol 33:304-310, 1999

• 34) Packer M, Bristow MR, Cohn JN et al; U.S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 35) Dupont A:Effects of carvedilol on renal function. Eur J Clin Pharmacol 38 (Suppl 2):S96-S100, 1990

• 36) Aranki SF, Shaw DP Adams DH et al:Atrial fibrillation after coronary artery surgery:current trends and impact on hospital resources. Circulation 94:390-397, 1996
  pubmed

• 37) 瀬尾裕之, 宮本覚, 八百秀樹ほか:開心術後の心房細動に対する短時間作用型β1遮断薬landiolol hydrochlorideの治療経験. 医と薬学 59:115-118, 2008

• 38) 西崎和彦, 島田和嘉, 田村大和ほか:心臓血管手術後の頻脈性心房細動に対するlandiololの効果. 新薬と臨 57:331-337, 2008

• 39) 田中恒有, 入江嘉仁, 大喜多陽平ほか. 心拍動下冠動脈バイパス術における塩酸ランジオロール〜低用量持続投与での有効性の検討〜. 新薬と臨 57:136-141, 2008

• 40) 内田徹郎, 深沢学, 川原優ほか:周術期管理に超短時間作用型β遮断薬landiololが有効であった大動脈弁狭窄例. 胸部外科61:1109-1113, 2008

• 41) 岩崎雄樹, 中田淳, 吉田明日香ほか:急性心筋梗塞に合併した発作性心房細動の臨床背景とその治療成績-超短時間作用型β遮断薬Landiololの有用性について (報告集第27回東京CCU研究会)-(CCU管理) . ICUとCCU 32:876-880, 2008

• 42) 三輪陽介, 池田隆徳, 米良尚晃ほか:難治性心室性不整脈に対する静注用超短時間作用型β1遮断薬ランジオロールの効果. 心臓 40 (Suppl 3):S148-S155, 2008

• 43) 久保慶高, 柿野俊介, 菅原淳ほか:くも膜下出血後脳血管攣縮期の頻脈性不整脈治療における塩酸ランジオロール (オノアクト(R)) の使用経験. 新薬と臨 57:152-155, 2008

• 44) Sanui M, Matsuo K, Sunagawa H:Low-dose landiolol for hypertention with tachycardia following neurosurgery. J Anesth 22:195-196, 2008

• 45) 山田和彦, 森和彦, 八木浩一ほか:食道サルベージ手術後の発作性心房細動に対して塩酸ランジオロールが有効であった1例. Prog Med 27:193-195, 2007

• 46) Yoshida Y, Hongo T, Sakamoto A et al:Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol. Anesth Analg 1OO:294, 2005

• 47) Cooley DA, Hency WS, Amad KH et al:Ventricular aneurysm following myocardial infarction:results of surgical treatment. Ann Surg 150:595-612, 1959

• 48) Dor V, Saab M, Coste P et al:Left ventricular aneurysm:anew surgical approach. Thorac Cardiovasc Surg. 37:11-19, 1989

• 49) Suma H:RESTORE Group:Left ventriculoplasty for nonischmeic dilated cardiomyopathy. Semin Thorac Cardio vasc Surg 13:514-521, 2001

• 50) Matsui Y, Fukada Y, Suto Y et al:Overlapping cardiac volume reduction operation. J Thorac Cardiovasc Surg 124:395-397, 2002
  pubmed

• 51) Ueno T, Sakata R, Iguro Y et al:Mid-term changes of left ventricular geometry and function after Dor, SAVE, and Overlapping procedures. Eur J Cardiothorac Surg 32:52-57, 2007
  pubmed

• 52) Radack K, Deck C:β-Adrenergic blocker therapy dose not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of r andomized controlled trials. Arch Intern Med 151:1769-1776, 1991 354

P.361 掲載の参考文献

• 1) Abraham WT, Fisher WG, Smith AL et al; MIRACLE Study Group:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002

• 2) Cleland JG, Daubert JC, Erdmann E et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators:The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539-1549, 2005

• 3) Bristow MR, Saxon LA, Boehmer J et al; Comparisonof Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators:Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140-2150, 2004
  pubmed

• 4) Aranda JM Jr, Woo GW, Conti JB et al:Use of cardiac resynchronization therapy to optimize betablocker therapy in patients with heart failure and prolonged QRS duration. Am J Cardiol 95:889-891, 2005
  pubmed

• 5) Piccini JP, Hernandez AF, Dai D et al; Get With the Guidelines Steering Committee and Hospitals:Use of cardiac resynchronization therapy in patients hospitalized with heart failure. Circulation 118:926-933, 2008

• 6) Wilkoff BL, Cook JR, Epstein AE et al; Dual Chamber and VVI Implantable Defibrillator Trial Investigators:Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator:the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288:3115-3123, 2002
  pubmed

• 7) Takemoto Y, Hozumi T, Sugioka K et al:Betablocker therapy induces ventricular resynchronization in dilated cardiomyopathy with narrow QRS complex. J Am Coll Cardiol 49:778-783, 2007
  pubmed

• 8) Cleland J, Freemantle N, Ghio S et al:Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol 52:438-445, 2008

• 9) Echt DS, Liebson PR, Mitchell LB et al:Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788, 1991

• 10) Kies P, Bax JJ, Molhoek SG et al:Effect of left ventricular remodeling after cardiac resynchronization therapy on frequency of ventricular arrhythmias. Am J Cardiol 94:130-132, 2004
  pubmed

• 11) Arya A, Haghjoo M, Dehghani MR et al:Effect of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator. Heart Rhythm 2:1094-1098, 2005
  pubmed

• 12) Medina-Ravell VA, Lankipalli RS, Yan GX et al:Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization:does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?Circulation 107:740-746, 2003
  pubmed

P.366 掲載の参考文献

• 1) Yusuf S, Peto R Lewis J et al:Beta blockade during and after myocardial infarction:an overview of the ran-domized trials. Prog Cardiovasc Dis 27:335-371, 1985

• 2) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blockers:importance of ancillary properties. Prog Cardiovasc Dis 39:445-45, 1997

• 3) Freemantle N, Cleland J, Young P et al:β Blockade after myocardial infarction:systematic review and meta regression analysis. BMI 318:1730-1737, 1999

• 4) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

• 5) Packer M, Bristow MR, Cohn JN et al;U. S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996

• 6) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999

• 7) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet 353:2001-2007, 1999

• 8) Packer M, Coats AJ, Fowler MB et al; Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 9) Packer M, Fowler MB, Roecker EB et al;Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group:Effect of carvedilol on the morbidity of patients with severe chronic heart failure:results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194-2199, 2002

• 10) Flather MD, Shibata MC, Coats AJ et al;SENIORS Investigators:Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) . Eur Heart J 26:215-225, 2005
  pubmed

• 11) The Antiarrhythmics versus lmplantable Defibrillators ( AVID ) Investigators:A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl JMed 337:1576-1583, 1997

• 12) Moss AJ, Hall WJ, Cannom DS et al; Multicenter Automatic Defibrillator Implantation Trial Investigators:Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335:1933-1940, 1996
  pubmed

• 13) Buxton AE, Lee KL, Fisher JD et al; Multicenter Unsustained Tachycardia Trial lnvestigators:A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341:1882-1890, 1999
  pubmed

• 14) Moss AJ, Zareba W, Hall WJ et al; Multicenter Automatic Defibrillator Implantation Trial ll Investigators:Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883, 2002

• 15) Kadish A, Dyer A, Daubert JP et al; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators:Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151-2158, 2004
  pubmed

• 16) Bardy GH, Lee KL, Mark DB et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators:Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237, 2005

• 17) 不整脈の非薬物治療ガイドライン (2006年改訂版):循環器病の診断と治療に関するガイドライン (2005年度合同研究班報告) <http://www.j-circ.or.jp/guidelinepdf/JCS2006_kasanuki_h.pdf>

• 18) Gregoratos G, Abrams J, Epstein AE et al:ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices:summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) . Circulation 106:2145-2161, 2002

• 19) Connolly SJ, Dorian P, Roberts RS et al; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators:Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators:the OPTIC Study:a randomized trial. JAMA 295:165-171, 2006

Part 13 β遮断薬使用上の注意点

P.373 掲載の参考文献

• 1) Packer M, Coats AJ, Fowler MB et al; Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

• 2) Hori M, Sasayama S, Kitabatake A et al:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004
  pubmed

• 3) Mancia G, De Backer G, Dominiczak et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the management of arterial hypertension. J Hypertens 25:1105-1187, 2007

• 4) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009

• 5) Shabsigh R, Perelman MA, Lockhart DC et al:Health issues of men:prevalence and correlates of erectile dysfunction. J Urol 174:662-667, 2005
  pubmed

• 6) Imai Y, Watanabe N, Hashimoto J et al:Muscle cramps and elevated serum creatine phosphokinase levels induced by β-adrenoceptor blockers. Eur J Clin Pharmacol 48:29-34, 1995

P.377 掲載の参考文献

• 1) Wagner F, Kalusche D, Trenk D et al:Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 24:213-220, 1987
  pubmed

• 2) Hemeryck A, Lefebvre RA, De Vriendt C et al:Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 67:283-291, 2000
  pubmed

• 3) Brodde OE, Kroemer HK:Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung 53:814-822, 2003
  pubmed

• 4) Bachmakov I, Werner U, Endress B et al:Characterization of β-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 20:273-282, 2006

• 5) Bader FM, Hagan ME, Crompton JA et al:The effect of β-blocker use on cyclosporine level in cardiac transplant recipients. J Heart Lung Transplant 24:2144-2147, 2005

• 6) 藤村昭夫, 須藤俊明, 杉本孝一ほか:不整脈. 疾患別これでわかる薬物相互作用 (第3版), 藤村昭夫編, 日本医事新報社, 東京, 2006, p.92-p.127